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Lung cancer is the second most common cancer and the leading cause of cancer mortality in 
the United Kingdom. Non-small cell lung cancer (NSCLC) accounts for over 80% of lung 
neoplasms. The high mortality is largely due to detection of the disease at advanced stages 
and resistance to drugs used in the treatment of the disease. Suitable biomarkers 
(diagnostic, prognostic and therapeutics) are therefore needed for the management of the 
disease.  
Long non-coding RNAs (lncRNAs) are involved in the regulation of numerous biological 
processes and have been implicated in the pathogenesis of many human diseases such as 
cancer. While the list of deregulated lncRNAs in NSCLC is increasing, most studies lack 
validation. In addition, the mechanisms involved in deregulation in most of these lncRNAs 
still needs to be elucidated. This thesis was therefore aimed at identifying and validating 
lncRNAs that are deregulated in NSCLC, investigating the epigenetic causes of their 
deregulation and analysing the functional contribution to development of NSCLC and effect 
on cell phenotype and drug resistance.  
Following microarray screening of paired tumour and normal surgical tissues from 44 NSCLC 
patients, 20 induced and 30 repressed lncRNAs were discovered in tumours compared to 
normal tissues. Top 13 of the 50 lncRNAs (FEZF1-AS1, LINC01214, LOC105376287, PCAT6, 
LOC101927229, LINC00673, NUTM2A-AS1, RNF139-AS1, LANCL1-AS1, FENDRR, LINC00968, 
SVIL-AS1, and PCAT19) were selected for validation, following careful inspection of the 
annotation in databases and sequence verification in relation to the microarray probes used 
for each gene. Validation by qPCR was performed in sample pairs from 29/44 microarray 
patients (technical validation) and 38 independent patients. With the exception of 
LOC105376287 and RNF139, the remaining 11 targets were successfully validated in both 
groups. Levels of all validated lncRNAs were independent of patient age and histology, 
however; higher expression of FEZF1-AS1 was observed in males compared to females 
(Mann Whitney’s Test, p=0.02). Variable expression levels were observed for all validated 
lncRNAs in NSCLC cell lines and human bronchial epithelial cell line and its isogenic 
derivatives. Furthermore, the epigenetic influence on lncRNA deregulation study showed 
significant hypermethylation of the promoter regions of FEZF1-AS1 and FENDRR, and 
hypomethylation of NUTM2A-AS1 and LINC00673.  
LINC00968 was selected for exogenous overexpression in NSCLC cell line A549. Some of the 
derived clones demonstrated lower proliferation, however, not proportional to the level of 
LINC00968 expression. Suppression of migration and invasion was demonstrated for the 
clone with maximum expression of LINC00968, and anchorage independent assay showed a 
reduction in cell colony count for maximum expressing clone. LINC00968 overexpression did 
not correlate with resistance to 5FU, gemcitabine, cisplatin and vinorelbine, on the contrary, 
the presence of LINC00968 increased cell viability in methotrexate and pemetrexed treated 
A549 cells and sensitized the cells to the effects of hydrogen peroxide in an expression 
dependent manner. 
In conclusion, this study identified previously uncharacterized lncRNAs that are deregulated 
in NSCLC, showed that epigenetic modulation of lncRNAs is an important reason for their 
deregulation in NSCLC in a direct or indirect manner and that LINC00968 is involved in 
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1.1 Lung Cancer: Incidence and Mortality 
Lung cancer is a complex disease of the lung that arises from uncontrolled proliferation of 
abnormal cells that line the lungs and is associated with various genetic, epigenetic and 
cytological changes (Giaconne, 2012). It is the third most common cancer, following breast 
cancer in women and prostate cancer in men; and is the leading cause of all cancer 
mortalities in the United Kingdom (UK) among males and females [Figures 1.1 and 1.2] 
(Cancer Research, UK 2016a). It has continued to be associated with the highest mortality 
rates in the UK accounting for 22% and 19.4% of cancer deaths in the UK and Worldwide 
respectively (Cancer Research, UK 2016b). It is regarded largely as a disease of the elderly as 
over 60% of lung cancer cases are diagnosed in patients aged over 70 years (Ferlay, et al., 
2013). The lack of specificity of symptoms of this disease has made early detection difficult, 
the 5-year survival rate has improved slightly to 15.9% after over four decades compared to 
65%, 90% and 99% observed in colon, breast and prostate cancer respectively (Chheang & 
Brown, 2013; Chen et al., 2014a). Advances in high throughput technology, diagnosis, 
therapy and management have made only minimal improvements in overall survival 
(Giaconne,. 2012). 
1.2 Symptoms 
Although symptoms of lung cancer are not specific, initial symptoms observed include: 
persistent cough, shortness of breath, haemoptysis (coughing blood in the sputum), pain in 
the chest and ribs, loss of appetite, weight loss and extreme tiredness. These symptoms are 
followed by hoarseness, difficulty in swallowing, swollen lymph nodes. in advanced stages of 















1.3 Histological classification 
Lung cancer is generally classified into small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC), based on the differences observed in their clinical characteristics (which 
includes, the high response rate of SCLC to first-line chemotherapy, its early progression and 
poor prognosis). SCLC and NSCLC account for approximately 15% and 85% respectively of all 
lung cancer cases worldwide (Gazdar et al., 2017; Herbst et al., 2018). 
1.3.1 Small Cell Lung Cancer (SCLC) 
SCLC comprises lung cancer cells that are relatively small, contain dense neurosecretory 
granules and are very aggressive lung tumours (Figure 1.3). They are highly sensitive to 
chemotherapy at the initial stage of the disease (Abidin et al., 2010; Zhang & He, 2013a; 
Gazdar et al., 2017) and are also known as oat cell carcinomas, small cell anaplastic 
carcinomas or undifferentiated small cell carcinomas. SCLC is of neuroendocrine origin (i.e. 
they originate from the nerve cells or hormone producing cells of the lung), and therefore 
typically begin in the bronchi, at the centre of the chest (Park et al., 2011). SCLC is 
predominantly caused by smoking, and reports have associated increased amounts of 
cigarettes smoked per day and the duration of smoking to the risk of developing SCLC 















1.3.2 Non-Small Cell Lung Cancer (NSCLC) 
Although there are several types of NSCLC based on histological classifications, the three 
most common are lung adenocarcinoma (LADC), lung squamous cell carcinoma (LSCC) and 
large cell carcinoma (LCC) (Girard et al., 2016).  
Lung Adenocarcinoma 
LADC makes up 38.5% of lung cancer cases and is a more common type of primary lung 
cancer (Sardenberg et al., 2013). It arises from the peripheral lung tissues, appears glandular 
and is characterized by production of mucin (Figure 1.4). LADC has been associated with 
early and current smokers and is the only type of NSCLC associated with never-smokers. 
Presently a lot of emphasis is been placed on LADC for biomarker testing because of its 
prevalence and its association with Epidermal Growth Factor Receptor (EGFR) mutation, 
Kirsten rat sarcoma (KRAS) mutation and Anaplastic lymphoma kinase (ALK) rearrangement 
(Brandao et al., 2012; Dong et al., 2016; Herbst et al., 2018). 
A B 
Figure 1.3: H & E staining of (A) small cell lung cancer at 10X magnification 
compared to (B) Normal healthy lung cell at 10X magnification. While the small 
cell lung cancer is characterised by oat-shaped malignant cells, the normal lung 











Lung Squamous cell carcinoma 
LSCC also known as epidermoid carcinoma accounts for about 25% to 30% of all lung cancer 
cases and often originates from the squamous cells of the central part of the lung or either 
bronchi. It is majorly associated with smoking (Herbst et al., 2018). 
Large cell carcinoma 
LCC is most often diagnosed by exclusion, that is, if the tumour cells lack the phenotypic 
characteristics of LADC or LSCC, or the respective biomarkers associated with either lung 
LADC or LSCC (Chen et al., 2014) or from SCLC by its size. They make up approximately 5 - 




Figure 1.4: Representative H & E staining of (A.) 10x magnification of lung adenocarcinoma 




1.4 Risk factors 
1.4.1 Smoking 
There are several well-established factors responsible for the development of lung cancer; 
however, the single major cause of this disease is tobacco smoking.  About 80% of lung 
cancer deaths are attributed to smoking (Furrukh, 2013; WHO, 2016). There are over 5000 
chemicals and 60 known carcinogens in tobacco smoke, these chemicals like nicotine, tar, 
formaldehyde, nitrosamines, arsenic, hydrogen cyanide, polycyclic aromatic hydrocarbons, 
uranium etc. penetrate lung tissues, produce intermediates that react with deoxyribonucleic 
acid (DNA) bases or bind to specific receptors and cause DNA damage or stimulate signalling 
pathways that increase cell proliferation and survival (Sanner & Grimsrud, 2015). Although 
the rate of smoking in both males and females has significantly reduced in comparison to 
the 1970s, the gender gap has significantly narrowed due to increased rate of women 
smokers (Figure 1.5). 
 





1.4.2 Environmental Factors 
Other factors are environmental, which includes exposure to second-hand smoke, 
residential radon, radiation therapy and occupational exposure to chemicals like asbestos, 
arsenic, coal products, sulphur mustard (mustard gas), silica, chromium etc. (Straif et al., 
2009; Field & Withers, 2012; Spyratos et al., 2013). 
1.4.3 Genetic Factors 
Genetic predisposition to lung cancer is also another risk factor (Yang et al., 2013). Several 
studies have shown family history of lung cancer in lung cancer patients. Genome-wide 
association studies (GWAS) have been able to associate lung cancer development in 
smokers to their susceptibility to the disease, they have also reported an increased risk of 
development of the disease in first degree relatives (Thorgeirsson, 2008; Kanwal et al., 
2017). 
Through GWAS, chromosomal regions associated with lung cancer risk in smokers and 
never-smokers have been identified. Amos et al., in their study performed in Caucasian 
smoking population demonstrated significant association between single nucleotide 
polymorphisms (SNPs) in the 15q, 5p and 6p chromosomal regions and susceptibility to lung 
cancer (Amos et al., 2008). In an independent study of Asian smoking population, similar 
association was observed at the same loci (Hung et al., 2008). These regions (15q25.1, 
5p15.33 and 6p21.33) contain CHRNA5/ CHRNA3/CHRNB4, TERT/CLPTM1L and BAG6 
(previously known as BAT3/M5H5) genes respectively, which have been shown to be 
strongly associated with smoking quantity, nicotine dependence and lung cancer. CHRNA/ 
CHRNB (cholinergic receptor nicotinic alpha and beta) genes are nicotinic acetylcholine 
receptor subunits that can be stimulated by nitrosamines resulting in tumour growth (Wu et 
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al., 2014a; Bossé and Amos, 2018). Interestingly, the 5p15.33 susceptibility locus has been 
associated with lung adenocarcinoma, while 6p21 locus was shown to be strongly 
associated with lung squamous carcinoma (Timofeeva et al., 2012). Li et al., identified a SNP 
associated with neversmokers at the 13q31.3 chromosomal region which harbours the GPC5 
(Glypican Proteoglycan 5) gene. GPC5 is thought to contribute to lung cancer development 
by regulating certain signalling pathways (Wnt, Hedgehogs and Fibroblast growth factors) (Li 
et al., 2010). 
1.5 Diagnosis, Staging and Management 
Early diagnosis and accurate staging are necessary for the administration of appropriate 
therapy and the estimation of disease outcome, hence the continued development of 
strategies for early detection and the review of the tumour node metastasis (TNM) staging 
system. 
1.5.1 Diagnosis 
Initial screening for lung cancer is determined by carrying out a chest x-ray, low dose CT 
(computer tomography), an MRI (magnetic resonance imaging) or a PET (positron emission 
tomography) scan. Other screening methods include, bronchoscopy and liquid biopsies. 
(Silvestri et al., 2013; Blandin Knight et al., 2017). 
1.5.2 Lung Cancer Staging: TNM Staging 
The TNM staging system for NSCLC is a staging system internationally accepted for the 
determination of the disease stage, which is measured by the extent to which the disease 
has spread. The latest TNM staging (8th edition) developed by the International Association 
for the Study of Lung Cancer (IASLC) and approved by the American Joint Committee on 
Cancer (AJCC) and the Union for International Cancer Control (UICC) classifies NSCLC staging 
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into five major prognostic stages and these include 0, I, II, III and IV based on the absence/ 
presence of a tumour, nodal infiltration and the presence or absence of metastasis. And a 
further sub-classification to indicate the size of the tumour or the extent of metastasis 
(Detterbeck et al., 2017). 
Determination of T staging is based on the size of the primary tumour in long axis or its 
extent into adjoining structures like the chest wall, the T0 descriptor indicates absence of 
tumour to T4 where the tumour is ˃ 7cm. Nodal staging considers the degree of spread to 
the surrounding lymph nodes, while the M staging describes the presence of metastases 
beyond the surrounding lymph nodes (Table 1.1 and Figure 1.6 to 1.8). 
Table 1.1: TNM Classification of lung cancer, showing the different stages of the disease 
adapted from (Detterbeck et al. 2017) 
Anatomical Staging and Prognostic Groups 
Occult Carcinoma TX N0 M0 
Stage 0 Tis N0 M0 
Stage IA T1a (≤ 1cm) N0 M0 
T1b (˃ 1cm ≤ 2cm) N0 M0 
T1c (˃ 2cm ≤ 3cm) N0 M0 
Stage IB T2a (˃ 3cm ≤ 4cm) N0 M0 
Stage IIA T2b (˃ 4cm ≤ 5cm) N0 M0 
T3 N0 M0 
Stage IIB T1a/ T1b/ T1c N1 M0 
T2a/ T2b N1 M0 
Stage IIIA T1a/ T1b/ T1c N2 M0 
T2a/ T2b N2 M0 
T3 (˃ 5cm ≤ 7cm) N1 M0 
T4 (≥7cm) N0 M0 
T4 N1 M0 
Stage IIIB T1a/ T1b/ T1c N3 M0 
T2a/ T2b N3 M0 
T3 N2 M0 
T4 N1 M0 
Stage IIIC T3/ T4 N3 M0 
Stage IVA Any T Any N M1a/M1b 






Figure 1-6: Graphical representation of the TNM staging showing stages 0 to IIB. The 
presence of non-invasive adenocarcinoma and squamous carcinoma without nodal 
infiltration can be observed in stage 0, while increase in tumour size up to 7 cm 
with/without nodal infiltration is classified under stages IA to IIB. At these stages tumours 





Figure 1-7: Illustration of stages IIIA to IIIC classification of NSCLC. Stage IIIA to IIIC is 
characterised by large tumours greater than 7 cm associated with nodal infiltration 
(including spread to the mediastinum, diaphragm, heart, great vessels of the heart, trachea 
and ipsilateral peribronchial, hilar, mediastinal nodes) Detterbeck et al., 2017. 
 
 
Figure 1-8: Stages IVA and IVB in the TNM staging as shown above is characterised by 
metasis which is classed into the regional metastatic disease (M1a) characterised by 
presence of tumour in both lungs or pericardial pleural effusion, the solitary extrathoracic 
disease (M1b) where a single organ outside the thoracic region (viz the brain, liver, bone, 
adrenal and liver) is involved and the multiple extrathoracic disease (M1c) where multiple 
organs have been affected . 
1.5.3 Management 
The management employed in the treatment of NSCLC patients depends on the stage of the 
disease. Treatment options include surgical resection, radiofrequency ablation (RFA), 
radiotherapy, chemotherapy, targeted therapy and immunotherapy.  
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Surgical resection is the standard treatment option for stages I and II NSCLC, when the 
tumour is still localised, however, most NSCLC patients are diagnosed at a later stage when 
surgical resection alone cannot cure the disease (Lackey et al., 2013; Van Schil et al., 2013).  
RFA (an imaging guided technique) is a minimally invasive procedure also used for the 
treatment of NSCLC at the early stages of NSCLC in patients unable to undergo surgery (due 
to poor performance status); it requires the use of high frequency electrical currents 
producing heat through electrodes to destroy small cancer cells which are less than 2 cm in 
diameter (or <3cm as recommended by the American College of Chest Surgeons). The 1-, 3-, 
and 5-year survival rates after RFA therapy were reported to be 97.7%, 72.9% and 55.7% 
respectively (Dupuy et al., 2000; Howington et al., 2013; de Baere et al., 2013; Hiraki et al., 
2014).  
Radical radiotherapy is considered in early stage treatment of NSCLC in case of comorbidity 
in some patients or as an adjunct therapy in locally advanced disease; it can also be 
administered as part of a palliative measure in metastasized disease. Although there are 
different types of radiation therapy, advanced radiation techniques such as the stereotactic 
body radiation therapy (SBRT) (which involves the precise administration of high radiation 
doses to lung tumours in short durations as possible) have been shown to be a very 
effective treatment and attains similar results as surgery with minimal toxicity and damage 
to healthy lung tissues  (Amini et al., 2010; Zheng et al., 2014).  
Chemotherapy is used for patients with locally advanced NSCLC as well as in patients with 
metastatic NSCLC but having good performance status. Prior to the late 1990s, the singular 
line of treatment for lung cancer was the use of platinum-based combination chemotherapy 
(Cosaert et al., 2013) Cisplatin or carboplatin with a non-platinum based drug have been a 
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promising and well-established two-drug combination, they are still the first-line treatment 
for most patients with advanced stage (IIIB and IV) NSCLC (Rossi & Di Maio. 2016). However, 
current therapeutic interventions consider the different histologic sub types of NSCLC and 
the involvement of driver mutations if known, this kind of treatment is referred to as 
targeted therapy. Typical examples are the epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors used as first-line therapy for patients with advanced lung 
adenocarcinomas with EGFR mutations and Crizotinib which has been approved by the US 
Food and Drug Administration (FDA) for advanced adenocarcinomas with anaplastic 
lymphoma kinase (ALK) rearrangements (Travis et al. 2012; Chan & Hughes, 2015). 
1.6 Epigenetics and Epigenetic Biomarkers 
In recent years, epigenetics has emerged as a major concept in the understanding of normal 
developmental processes as well as disease development and progression (Liloglou et al., 
2014). Lung cancer, much like any other cancer, is now known to develop through a series of 
genetic and epigenetic alterations resulting in qualitative changes in the function of many 
genes (Langevin et al., 2015). 
Conrad Waddington first used the term epigenetics and defined it “as change in phenotype 
without change in genotype” (Waddington, 2012; Goldberg et al., 2007). Today, epigenetics 
is defined as the study of stable heritable alterations in gene expression without 
corresponding change in the DNA sequence (Jaenisch & Bird, 2003). Epigenetic mechanisms 
like DNA methylation, histone modification, chromatin remodelling and non-coding RNAs 
have been shown to control gene expression patterns (Liloglou et al., 2014). 
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1.6.1 DNA Methylation 
DNA methylation is an epigenetic mechanism that involves the covalent addition of a methyl 
group from S-adenosyl-L-methionine (SAM) to the fifth carbon atom of a cytosine ring of 
DNA resulting in the formation of 5-methylcytosine (5mC). This process is catalysed by DNA 
methyltransferases (DNMTs) encoded in many genomes of bacteria, plants and mammals; 
and the conservation of these enzymes is an indication of the importance of DNA 
methylation in the organism (Figure 1.9) (Jin et al., 2011; Zhu et al., 2016; Zhang and Xu, 
2017).  
 
Figure 1-9: Chemical illustration of DNA methylation at the 5 position of cytosine catalysed 
by DNMT in the presence of SAM (Zakhari, 2013). 
 
As a very important epigenetic factor and stable repressive mark, DNA methylation is 
essential in regulating gene expression for proper mammalian development (e.g., genomic 
imprinting and X-chromosome inactivation in females) and plays a role in maintaining 
genomic stability; it closely interacts with histone modification and chromatin-remodelling 
complexes to regulate the proper functioning of the genome (Esteller, 2005; Tost, 2009; 
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Kulis & Esteller, 2010). However, dysregulation of DNA methylation has been shown to be 
linked to several diseases including cancer (Jin et al., 2011; Hernando-Herraez et al., 2015). 
1.6.2 DNA Methyltransferases (DNMTs) 
DNA Methyltransferases (DNMTs) are a family of enzymes (DNMT1, DNMT3A, DNMT3B and 
DNMT3L) responsible for the transfer of a methyl group from SAM to the 5 position of 
cytosine (Jin & Robertson, 2013). Although they are similar structurally, they differ in their 
functions and expression patterns. DNMT1 is responsible for the replication of the DNA 
methylation pattern from the parent DNA (hemimethylated DNA) to the newly synthesized 
DNA strand, it is involved in the maintenance and repair of DNA methylation (Goll & Bestor, 
2005). DNMT3A and DNMT3B are known as de novo DNMTs and play a role in establishing 
new methylation patterns to unmodified DNA (Moore et al., 2013). DNMT3L is an enzyme 
that in human is encoded in the DNMT3L gene, expressed solely in germ cells and functions 
as a regulatory factor. Although it lacks detectable cytosine methyltransferase activity, it 
stimulates de novo methylation by DNMT3A (Gujar et al., 2019). 
1.6.3 DNA Methylation and Cancer 
In cancer, DNA hypermethylation in the upstream promoter region is associated with 
silencing of growth regulators like tumour suppressor genes (Figure 1.10) (Baylin, 2005; 





Figure 1.10: DNA hypermethylation can be seen in the CpG islands in tumour cell and gene 
silencing effect. White circles are unmethylated cytosine, while red circles are methylated 
cytosines (Moison et al., 2014). 
 
It mainly occurs in CpG islands (CGI) of many gene promoters (which are most often, largely 
unmethylated during normal development and in adult cells) preventing the binding of 
transcription factors to DNA and subsequent transcription inactivation and gene silencing 
(Pfeifer, 2018). Gene silencing occurs as a result of the methylation of cytosine dinucleotides 
in the promoter region; however, there can be gene body methylation where methylation 
occurs at the transcribed regions (after the first exon) resulting in either silencing of two or 
more alternative promoters of a gene or retrotransposon elements; or increased gene 
expression in rapidly dividing cells at a global genome scale. The former resulting in a 
change in expression of specific transcript isoforms, while the latter may promote 
oncogenesis if the methylated genes have oncogenic properties (Moore et al., 2013; Pfeifer, 
2018). Detailed knowledge of the relations between methylation and gene expression, and 
the triggers for the changes in methylation associated with development and progression 
for the multitudes of cancers remains largely unclear. 
1.7 Non-Coding RNAs (ncRNAs) 
The completion of the Encyclopaedia of DNA Elements (ENCODE) project revealed that only 
about 2% of the human genome has protein-coding potential, while the rest of the genome  
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is made up of repetitive transposable elements (RTEs) and ncRNAs (The Encode Project 
Consortium, 2012; Rinn, & Chang, 2012; Richard, 2017). The non-protein-coding regions of 
the genome are believed to serve as substrates for DNA-binding proteins (that control the 
expression and 3D architecture of the genome) as well as a template for the transcription of 
vast numbers of ncRNAs that are capable of carrying out a wide array of regulatory 
functions (Carninci et al., 2005; Amaral et al., 2008; Mercer et al., 2009). 
ncRNAs are basically classified into two major categories based on their length; small 
ncRNAs which are less than 200 nucleotides in length (~<200 nt in length) and long ncRNAs 
(lncRNAs) that are equal to or greater than 200 nucleotides in length (~≥200 nt). The 
smallest ncRNAs include RNAs of 20–30 nucleotides which are involved in RNA silencing; 
e.g., microRNA (miRNA), small interfering RNA (siRNA) and PIWI (P-element-induced wimpy 
testis)-interacting RNAs (piRNA); other small ncRNAs of 100–200 nucleotides include the 
abundant housekeeping ncRNAs like transfer RNAs(tRNAs), ribosomal RNAs (rRNAs) and the 
ncRNAs classified based on their subcellular localization; i.e. small nuclear RNA (snRNA), 
small nucleolar RNA (snoRNA), and small cytoplasmic RNA (scRNA) (Table 1.2) (Gutschner & 
Diederichs, 2012; Yoshimoto et al., 2015; Hombach & Kretz, 2016).  Despite the discovery of 
several classes of small ncRNAs; miRNAs, piRNAs and siRNAs are generally recognized as the 
three main categories of small ncRNAs due to their biogenesis, structure, function and 
associated effector proteins (Carthew & Sontheimer, 2009). 
1.7.1 RNA interference (RNAi) Pathway 
RNAi also known previously as Post Transcriptional Gene Silencing (PTGS) is an evolutionary 
conserved biological process that triggers gene silencing by small RNA molecules (double-
stranded RNA and pre-miRNA precursors). It was initially discovered in fungi and plants and 
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subsequently in Caenorhabditis elegans, Drosophillia and finally in the mammals. siRNAs 
and miRNAs are processed from long dsRNA and pre-miRNA respectively. While siRNA is 
cleaved into short double-stranded fragments of about 21 nucleotides in length by the 
RNAse III enzyme Dicer, miRNA processing is catalysed by Drosha in the nucleus and Dicer in 
the cytoplasm (Kim and Rossi, 2007; NCBI 2017). 
The dsRNA molecules are separated into two single-stranded RNA having 2nt overhang on 
the 3’ end of each strand; the passenger strand is degraded, while the guide strand is 
incorporated into a multi-protein silencing complex known as RNA-induced silencing 
complex (RISC). The RISC complex is guided to the target mRNA in a sequence-specific 
manner, and the mRNA is cleaved by Argonaute 2a member of the Argonaute protein family 
important in RNAi, regulation of stem cell development and tumorigenesis. On the other 
hand, pre-miRNAs in the cytoplasm are enzymatically cleaved by Dicer into mature miRNA 
which then binds to RISC. The miRNA-RISC complex binding to a target mRNA inhibits 
translation thereby silencing the gene (Dana et al., 2017; Kim and Kim, 2012). 
1.7.2 MicroRNAs 
miRNAs are small ncRNAs that were first discovered in C. elegans, they are 18–25 
nucleotides long, single-stranded, endogenous, and evolutionarily conserved (Bartel, 2004). 
They target protein-coding mRNAs at the post-transcriptional level and bind to the 3′-
untranslated regions (3′ UTRs) resulting in target mRNA repression and consequently 
translational inhibition and gene silencing (Ricciuti et al., 2014; Ha & Kim, 2014). miRNAs are 
well characterised, and the best studied of all the small ncRNAs, they have been shown to 
either act as tumour suppressors or oncogenic initiators when dysregulated. To date over 
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2,469 new human miRNAs have been reported, with over 1,098 validated (Friedlander et al., 
2014;  Bracken et al., 2016; O'Brien et al., 2018). 
1.7.3 Small interfering RNAs 
siRNAs also called silencing RNAs are 19- 25 nucleotides in length and are similar to miRNAs. 
They operate within the RNA interference pathway, leading to a sequence-specific 
degradation of complementary target mRNAs, thereby inhibiting translation (McManus et 
al., 2002; Rand et al., 2005; Dana et al., 2017) 
1.7.4 PIWI-interacting RNAs 
piRNAs are the most recent and longest class of small non-coding RNAs and are often 
expressed in the germline. They are 24–33 nucleotides long and are generated by Dicer-
independent mechanisms, unlike siRNAs and miRNAs. piRNAs interact only with PIWI clade 
proteins (a germ-line specific subfamily of Argonaute proteins) also involved in the gene-
silencing pathways (Moazed, 2009). It has been reported that there are over 30,000 piRNAs 
in the human genome, 80% of which developed from intergenic sequences. They are 
subdivided into three types based on their source of origin viz:- the transposon-derived 
piRNA from the, mRNA-derived piRNA and lncRNA-derived piRNA (Robine et al., 2009).  
Recent evidence has shown their role in the preservation of genomic integrity during 
germline development by silencing transposable elements (TEs) via the PIWI-piRNA pathway 
(Siomi et al., 2011; Iwasaki et al., 2015). 
The PIWI-piRNA pathway is a gene regulatory machinery that is important in inhibition of 
TEs (Sturm et al., 2017). The association between piRNA and the PIWI proteins induces the 
piRNA-induced silencing complex (pi-RISC) which enables the recognition of target mRNA for 
cleavage and eventual gene silencing. The PIWI-piRNA complex has also been reported to 
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regulate HP1, H3K9 and DNA methylation in the nucleus silencing transposable elements 
(Meseure and Alsiba, 2018). 
These molecules are important not only in regulation of gene expression and alternative 
splicing but also in epigenetic control and guidance of chromatin remodeling complexes, 
and have become potential target for diagnostics, prognostics and therapeutics. 
1.8 Long non-coding RNAs 
lncRNAs are common both in prokaryotic and eukaryotic genomes. They were originally 
discovered through large-scale sequencing of full-length cDNA libraries in mice and 
microarray tiling arrays (Gutschner & Diederichs, 2012; Kashi et al., 2016). lncRNAs share 
many features of mRNAs (they are frequently transcribed by RNA polymerase II, 
polyadenylated and can show complex splicing patterns), but lack functional open reading 
frames (ORF) (Cheetham et al., 2013). In comparison with mRNAs, lncRNAs are generally 
less abundant, more likely to be expressed in a tissue-specific manner, and poorly conserved 
between species (Ulitsky & Bartel, 2013; Yoshimoto et al., 2016). They are defined as 
endogenous cellular RNAs of more than 200 nucleotides in length (Gutschner & Diederichs, 
2012) based on RNA purification protocols which excludes small RNAs. However, recent 
studies have led to the redefining of lncRNAs to include “RNA molecules that may function 
as primary or spliced transcripts and do not fit into known classes of small RNAs or 
structural RNAs” examples like BCI and snaR having nucleotide lengths less than 200 
(Amaral et al., 2008; Quinn and Chang, 2016). 
They have been shown to be important in numerous biological processes (transcription, 
translation, splicing, imprinting), and have also been implicated in the development and 
progression of many diseases including cancer (Clark & Mattick, 2011; Chen et al., 2016). 
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lncRNAs often overlap with or are distributed between coding and non-coding transcripts. 
There are different types of lncRNAs based on their genomic location in relation to protein-
coding genes as shown in Figure 1.11 (Kung et al., 2013). These include (i) sense lncRNAs- 
which are transcribed from the sense strand of protein-coding genes and may overlap these 
genes; (ii) antisense lncRNAs also called Natural Antisense Transcripts [NATs]- that overlap 
one or more exons of a protein-coding gene on the opposite strand partially or completely; 
(iii) bi-directional lncRNAs- that are located on the opposite strand of a protein-coding gene 
and their transcription initiated in close genomic proximity [i.e. less than 1000 base pairs]; 
(iv) intronic lncRNAs- which are derived from an intron of a protein-coding gene; (v) 
intergenic lncRNAs-  that are transcribed from intergenic regions (between protein-coding 
genes) and more recently, (vi) enhancer lncRNAs and (vii) circular RNAs (Gutschner & 
Diederichs, 2012; Qiu et al., 2013; Ma et al., 2013; Schein et al., 2016; Lorenzen & Thum, 
2016).  
lncRNAs are also classified functionally into cis-acting and trans-acting based on the 
influence they exert on DNA sequences (Ma et al., 2013).  Cis-acting lncRNAs restrict their 
action to their site of synthesis and regulate the expression of genes on the same 
chromosomal location. Examples include Xist (X inactive-specific transcript), Tsix, ANRIL 
(antisense non-coding RNA in the INK4 locus), HOTTIP (HOXA transcript at the distal tip), 
COLDAIR (cold assisted intronic non-coding RNA) etc. However, trans-acting lncRNAs 
disperse from their site of synthesis and act directly on many genes at great distances, 
including other chromosomal locations. Examples of this class of lncRNAs are HOTAIR (HOX 
antisense intergenic RNA), GAS5 (growth arrest-specific transcript 5), Jpx and MALAT1 
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(Metastasis associated lung adenocarcinoma transcript 1) (Guil & Esteller, 2012; Lee, 2012; 
Vance & Ponting, 2014). 
 













Table 1.2: Types of ncRNAs (Adapted from (Esteller, 2011) 
Group Type Length 
(nt) 
Functions Examples References 
Short 
ncRNAs 
miRNA 18 – 25bp mRNA degradation and RNA 
silencing  
miR-15, miR-16, miR-21, 
miR-155 
(Calin et al., 2002; Lawrie et al., 2008; Volinia 
et al., 2006; Yanaihara et al., 2006) 
tiRNA 17 -18bp Regulation of transcription Associated with CAP1 genes (Taft et al., 2010) 
piRNA 24 -31bp Silencing of transposons and 
maintaining genome stability 
They exist as clusters (Sai Lakshmi & Agrawal, 2008; Luteijn & 
Ketting, 2013; Ross et al., 2014) 
Mid-size 
ncRNAs 
snoRNAs 60-300bp rRNA modifications U12, U50, SNORD115, 
SNORD116 
(Kiss-La¡szla et al., 1996) 
PASRs 22-200bp Transcriptional activation or 
repression 
Interact with 50% of 
polycomb group of proteins 
(Kapranov et al., 2007; Kaikkonen et al., 2011) 
TSSa-
RNAs 
20-90bp Maintenance of transcription Associated with RNF12 and 
CCDC52 genes 
(Seila et al., 2008) 
Long 
ncRNAs 
lincRNAs ˃200bp Regulation of gene expression 
by chromatin complex 
modification 
HOTAIR, MALAT1, lincRNA-
p21 and ANRIL 
(Khalil et al., 2009; Huarte et al., 2010; Tsai et 
al., 2010) 
T-UCRs ˃200bp Antisense inhibitors of protein 
coding genes 
uc.202, uc.328, uc. 230 (Braconi et al., 2011; Calin et al., 2007; Fassan 
et al., 2014) 
Other 
lncRNAs 
˃200bp X-chromosome inactivation, 
telomere regulation etc. 
XIST, TSIX, TERRAs, H19 (Rinn et al., 2007; Gupta et al., 2010) 
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1.8.1 Cellular functions and mechanisms of lncRNAs 
Despite the vast array of lncRNAs identified to date, much is yet to be understood about 
their function. Their conservation, however, has strengthened the debate over their 
functional relevance. Some of these transcripts are derived from ultra-conserved genomic 
regions (UCR) and their aberrant expression has been associated with numerous diseases 
including cancers (Braconi et al., 2011; Fang & Fullwood, 2016).  
It has become apparent that lncRNAs play an important role in regulating gene expression at 
various levels. They have been shown to be important in chromatin modification, as well as 
transcriptional and post-transcriptional regulation (Ponting et al., 2009; Chen & Carmichael, 
2010). There are several mechanisms that have been postulated that will aid the 
understanding of lncRNA functions (Cheetham et al., 2013). 
Chromatin Modification 
lncRNAs can act as scaffold molecules, controlling the delivery of regulatory proteins to 
specific loci where they are required to effect epigenetic changes either in cis or trans. 
lncRNAs like Xist, COLDAIR, HOTTIP, HOTAIR, KCNQ1OT1 (KCNQ1 overlapping transcript 1) 
interact with chromatin remodelling complexes resulting in heterochromatin formation in 
specific genomic loci consequently leading to reduction in target gene expression and gene 
silencing (Wang & Chang, 2011; Gutschner & Diederichs, 2012). ANRIL antisense transcript 
also known as CDKN2B-AS is an example of a lncRNA that acts as a scaffold. It recruits and 
binds to the chromobox 7 (CBX7) subunit of the PRC1 (Polycomb repressive complex 1) and 
SUZ12 component of PRC2 (Polycomb repressive complex 2). These complexes then direct 
H3K27me (methylation of histone H3 at Lys-27) to the target loci bringing about the 
silencing of sense transcripts expressed from this region (Yap et al., 2010). In a similar way, 
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HOTAIR binds to and recruits PRC2 and the LSD1 (lysine-specific demethylase 1)- a 
component of the CoREST (co-repressor for element-1-silencing transcription factor) 
complex. This brings about specific alterations in the methylation status of H3K27me, 
change in the nature of the chromatin surrounding the HOTAIR targets in the HOXD 
(homeobox D) cluster and consequent gene silencing (Rinn et al., 2007; Gupta et al., 2010; 
Fang & Fullwood, 2016). 
Regulation of Alternative Splicing 
Some lncRNAs act at post-transcriptional levels and function in RNA processing by 
controlling alternative splicing of pre-mRNAs (precursor mRNAs). A typical example is 
MALAT1 also known as NEAT2 (noncoding nuclear enriched abundant transcript 2), which 
interacts with the serine/arginine-rich (SR) splicing regulatory proteins (a member of the 
trans-acting protein factors) that control alternative splicing patterns. The interaction of 
MALAT1 with these factors results in their localization to nuclear speckles (mRNA processing 
site) and subsequent release when needed. Disruptions to the expression or activity of 
MALAT1 have been implicated in some cancers (Tripathi et al., 2010). More recently, 
Gonzalez et al, have reported the regulation of alternative splicing of FGFR2 mRNA 
(Fibroblast growth factor receptor 2) by a lncRNA asFGFR2 (antisense FGFR2) transcript via 
the recruitment of PRC2 and KDM2A to the FGFR2 locus (Gonzalez et al., 2015).  
Transcriptional Co-activation and inhibition   
lncRNAs can also acts as transcriptional co-activators or inhibitors, their expression has been 
reported to be induced by transcriptional factors in response to specific stimuli as a result of 
DNA damage. An Example is the lincRNA-p21 (long intergenic non-coding RNA p21) that 
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possesses p53 binding sites in its promoter and is directly induced by p53. lincRNA-p21 
consequently represses genes that inhibit cell cycle arrest and apoptosis by binding to 
heterogeneous nuclear ribonucleoprotein K (hnRNP-K) (Huarte et al., 2010; Liu & Lu, 2012; 
Quan et al., 2015). 
Decoy Molecules 
lncRNAs have also been reported to affect the transcription process by acting as decoys and 
sequestering transcription factors from degradation by target genes or competing for the 
binding sites of these transcription factors (Kung et al., 2013).  Examples include, PTENP1 
(phosphatase and tensin homolog pseudogene 1) which binds to miRNAs that downregulate 
PTEN (a tumour suppressor gene) thereby increasing expression of PTEN (Poliseno et al. 
2010). Gas5 acts as a decoy by binding to the DNA binding domain of glucocorticoid 
receptor and inhibiting the binding of glucocorticoid response elements thereby modulating 
its activity (Kino et al., 2010). 
1.8.2 lncRNAs and Cancer 
Aberrant expression of lncRNAs in cancer had been reported before the availability of high-
throughput sequencing technologies; H19, PCA3 (prostate cancer associated 3), MALAT1 
were shown to be over expressed in tumours (Zhang et al., 1993; de Kok et al., 2002; 
Bartonicek et al., 2016). However, increasing numbers of dysregulated lncRNAs have now 
been identified in cancer tissues and cell lines through genome-wide transcriptome analyses 
(Qiu et al., 2013; Huarte, 2015; Bartonicek et al., 2016).  In view of the large-scale 
dysregulation of lncRNAs in different cancers, it is plausible to infer that lncRNAs are not just 
secondary effects of cancer but are involved in tumorigenic or metastatic processes. 
However, lncRNA research is still at the cradle stage and only a relatively small number of 
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these group of transcripts have been characterized and their role in cancer fully understood, 
despite the large array of lncRNAs identified to date. 
1.8.3 Examples of Well Characterized lncRNAs Deregulated in Cancer 
MALAT1: MALAT1 (Metastasis-associated lung adenocarcinoma transcript 1) also known as 
NEAT2, is an 8.7 kb lncRNA gene that is located on chromosome 11q13 (GeneCard, 2017). It 
has been previously reported to contribute to tumour development, invasion and 
metastasis. It was shown to be over-expressed in non-small cell lung cancer and this was 
associated with metastasis and poor prognosis in a histology-specific manner (Ji et al., 
2003), it was further reported to promote cell motility of lung cancer cells (Tano et al., 
2010).  A study by Schmidt et al., (2011) revealed the role of the metastasis marker as a 
potential key player in the metastatic process. MALAT1 is also over-expressed in ovarian 
cancer (Zhou et al., 2016), breast cancer (Meseure et al., 2016) and colorectal cancer (Ji et 
al., 2014). MALAT1 has been shown to be involved in the modulation of several molecular 
signalling pathways, resulting in the modification of different associated cancer phenotypes 
(Li et al., 2018). In lung cancer, MALAT1 knock down in cisplatin-resistant A549/DDP cells is 
shown to increase cisplatin sensitivity through upregulation of miR-101-3p and MCL1 
downregulation (Wang et al., 2017). Although MALAT1 may not be an independent 
diagnostic biomarker in NSCLC as a result of its low sensitivity based on small sample size, it 
has been shown to be a potential prognostic biomarker (Lin et al., 2018). 
HOTAIR: The HOX antisense intergenic RNA (HOTAIR) is a 2.2 kb transcript which is 
transcribed from HOX C gene cluster on chromosome 12 and was first identified by Rinn and 
colleagues (Rinn et al., 2007; GeneCard, 2017). The HOTAIR gene was found to be over-
expressed in breast cancer (Gupta et al., 2010), oesophageal cancer (Chen et al., 2013) 
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hepatocellular cancer (Yang et al., 2011) and its high expression correlated with metastasis, 
recurrence, and poor prognosis. 
PTENP 1: PTENP1 is the pseudogene of the tumour suppressor gene PTEN (phosphatase and 
tensin homolog) and is located on chromosome 9p13.3 (GeneCard, 2017). Highly similar to 
PTEN with homology of ~98% at the 3’ untranslated region (3’UTR), it has been shown to 
function as a “decoy” interacting with miRNA miR21 that represses PTEN, thereby increasing 
the expression of PTEN (Poliseno et al., 2010; Gao et al., 2017). Its reduced expression has 
been associated with poor survival outcomes in head and neck squamous cell carcinoma (Liu 
et al., 2017) and increased proliferation and metastasis in clear-cell renal cell carcinoma (Yu 
et al., 2014). 
1.8.4 lncRNAs Deregulated in NSCLC 
Apart from the well characterized MALAT1 in lung cancer, there are other lncRNAs that have 
also been identified to be deregulated in NSCLC but are yet to be fully studied (Table 1.3). 
PVT1: The PVT1 (plasmacytoma variant translocation 1) lncRNA encoded in the PVT1 gene 
located on chromosome 8q24.21, has been reported to be upregulated in a large variety of 
human tumours (Colombo et al., 2015; Yang et al., 2019). 
Takahashi et al., showed that colorectal cancer patients with high PVT1 expression had 
significantly poorer prognosis than those with low PVT1 expression (Takahashi et al., 2014). 
Wang et al., revealed that PVT1 could promote cell proliferation, cell cycling, and the 
acquisition of stem cell-like properties in hepatocellular carcinoma cells by stabilizing NOP2 
protein (Wang et al., 2014; Colombo et al., 2015). 
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Studies carried out by Cui et al., showed significant increase in PVT1 levels in NSCLC tissues 
and cell lines (A549, H157, H226, H460, and HCC827). Their results further revealed that 
elevated PVT1 level was associated with poor overall survival and advanced T-stage and 
tumour-node-metastasis. It has also been previously reported to possess oncogenic 
properties in numerous cancers, with its overexpression resulting in the promotion of cell 
proliferation and cell cycle progression in NSCLC (Cui et al., 2016). Wan et al., in their 
findings also showed that regulation of LATS2 (large tumour suppressor kinase 2) by PVT1 
through its interaction with EZH2 was responsible for the promotion of cell proliferation by 
PVT1 (Wan et al., 2016). 
HOXA11-AS1: HOXA11 antisense 1 is located on chromosome7p15.2 and transcribed from 
the antisense strand of the HOXA11 gene. It has been shown to inhibit oncogenic phenotype 
in ovarian cancer (Richards et al., 2015) and is a potential biomarker target for glioma 
progression (Wang et al., 2016). Zhang et al., in their study based on microarray and other 
bioinformatic data, as well as original data obtained from The Cancer Genome Atlas (TCGA) 
reported its upregulation in LAD and LSCC. Further studies showed they were upregulated in 
NSCLC tumour tissues compared to the paired normal tissues and that they could drive the 
development and progression of NSCLC by regulating DOCK8 expression (Zhang et al., 2016; 











Lung cancer Type Sample No References 
MALAT1 Upregulated Adenocarcinoma 70 
(Ji et al., 2003; 





(Nakagawa et al., 
2013) 
ANRIL Upregulated - 68 (Nie et al., 2015) 
SOX2OT Upregulated Squamous cell carcinoma 83 (Hou et al., 2014) 
HNF1A-
AS1 
Upregulated Adenocarcinoma 40 (Wu et al., 2015) 
PVT1 Upregulated - 82 (Yang et al., 2014) 
H19 Upregulated Squamous cell carcinoma 70 (Zhang et al., 2016) 




76 (Li et al., 2017a) 
MEG3 Downregulated - 44 (Lu et al., 2013) 
SPRY4-
IT1 




72 (Shi et al., 2015) 








A novel lncRNA reported to be downregulated in epithelial ovarian cancer and associated 
with poor prognosis, has now been shown to also be downregulated in NSCLC. 
Overexpression of this gene in A549 and NCI-H1299 cell lines was associated with reduced 
proliferation (Chen et al., 2017). 
BCAR4  
Breast cancer anti-oestrogen resistance 4(BCAR4) located on chromosomal position 
16p13.13 has been implicated in breast cancer metastasis via chemokine mediated binding 
of BCAR4 to transcription factors (TFs) SNIP1 and PNUTS (Xing et al., 2014). More recently, 
this lncRNA has been shown to be upregulated in NSCLC and promotes proliferation, 
invasion and metastasis (Li et al., 2017a). 
miR31HG 
miR31HG also known as LOC554202 is a 2,246 bases lncRNA located on chromosome 9p21.3 
and is known to encapsulate miR31 in its first intron and contain a CpG island in its first 
exon. It has been reported to be present in the nucleus and cytoplasm of fibroblasts and to 
be downregulated in triple-negative breast cancer (TNBC) cell lines of luminal subtype 
(Montes et al., 2015). However, Shi et al., showed upregulation of miR31HG in breast cancer 
tissues compared to paired normals (Shi et al., 2014). Recent studies by Wang et al., 
revealed that miR31HG was differentially expressed in gefitinib-sensitive and gefitinib-
resistant PC9 cell lines respectively and that increased expression of miR31HG resulted in 
gefitinib resistance in the NSCLC cell line through the EGFR/P13K/AKT signalling pathway 




Sprouty4-Intron 1 is a long non-coding RNA that is transcribed from the intron of the SPRY4 
gene. It has been shown to be overexpressed in different kinds of tumour tissues (including 
melanoma, breast cancer, gastric cancer, colon cancer, hepatocellular carcinoma and 
NSCLC) ( Xie et al., 2015; Cao et al., 2016;  Li et al., 2017b). 
XLOC_008466  
It has also been shown to be upregulated and to have oncogenic properties in cervical 
cancer (Guo et al., 2018). It has been reported to be upregulated in NSCLC tumours and 
functions as an oncogene in NSCLC (Yang et al., 2017a). 
1.8.5 lncRNAs: as biomarkers for early detection 
A biomarker is a biological molecule found in blood, other bodily fluids or tissues, that can 
be used to measure and evaluate normal or abnormal biological processes objectively. They 
can be used for screening, prediction of disease outcome, diagnostic or therapeutic 
purposes (Strimbu & Tavel, 2010). 
Current diagnostic tools for NSCLC include the use of imaging techniques or body fluid 
analysis, at which time the disease may have metastasized, and available treatment options 
cannot provide a cure. Therefore, the development of non-invasive molecular biomarkers 
for early detection of NSCLC is a major translational research challenge. The recent evidence 
on the extent of lncRNA deregulation in NSCLC provisionally makes them worth investigating 
for biomarker properties. They, however, must be specific, sensitive, and detectable in 
specimens obtained through minimally invasive procedures to be clinically useful as 
biomarkers (Mazzone et al., 2017). 
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Some lncRNAs have been identified as potential non-invasive biomarkers for early detection 
of cancer. A typical example, is the FDA approved prostate cancer antigen 3 (PCA3) also 
known as DD3, a prostate cancer specific lncRNA first identified in 1999 and is present at 
high levels in prostate cancer tissues (Deng et al., 2017; Bolha et al., 2017). Since prostate 
specific antigen (PSA), which is the frequently used biomarker for prostate cancer is prostate 
specific, the PCA3 is used to determine if the PSA increase is due to prostate cancer. As a 
biomarker for early detection of prostate cancer, it can be detected by RT-qPCR in urine or 
urine sediments obtained after prostatic massage or digital rectal examination (Tinzl et al., 
2004; Marks et al., 2007; van Gils et al., 2007). 
lncRNA16 is a lncRNA that has been identified as a potential biomarker for the early 
detection of lung cancer. Studies carried out by Zhu et al, showed lncRNA16 to be highly 
expressed in lung tissues and elevated in plasma of lung cancer patients. They further 
demonstrated that lncRNA16 was detected at the ground glass opacity, early and advanced 
stage of the disease making it a suitable biomarker for early detection. As a diagnostic 
biomarker, lncRNA16 was found to have 73.97% and 100% sensitivity and specificity 
respectively when compared to currently used tumour markers like carcinoembryonic 
antigen (CEA) and cancer antigen 125 (CA125)(Zhu et al., 2017). 
1.9 Hypotheses 
Deregulation of long non-coding RNAs is extensive in NSCLC and many of these lncRNAs may 
be drivers of the development and progression of NSCLC. 
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1.10 Aim and Objectives 
The aim of this study is to identify novel lncRNAs that are deregulated in NSCLC and 
evaluate their role in lung carcinogenesis. 
Objectives of this study are: - 
 To evaluate expression profile of identified lncRNAs in primary NSCLC tissues and 
adjacent normal tissues, NSCLC cell lines and explore their biomarker potential. 
 To investigate the epigenetic causes of the deregulation in the identified lncRNAs. 
 To analyse the functional contribution of chosen lncRNA target to the development 




















2. MATERIALS AND METHOD 
2.1. Materials and Instruments 
Absolute Ethanol 
Agarose (Sigma-Aldrich) 
Agilent RNA 6000 Nano kit (Agilent Technologies) Catalogue No. 5067-1511 
Ampicillin 
Annealing Buffer (Qiagen) 
Beakers 
Bioanalyzer 2100 (Agilent Technologies) 
CO2 Incubator 
Corning Cryogenic Vials 
Decitabine (5-aza-2-deoxycytidine) (Sigma Aldrich) Catalogue No. 11390 
DEPC (diethyl pyrocarbonate) Water 
Direct-zol RNA miniprep kit (Zymo Research) Catalogue Nos. R2050-R2053 
Dri-Block DB-2A (Techne) 
Dulbecco’s Modified Eagle's Medium (DMEM) (Sigma-Aldrich) 
Electrophoresis Chamber  
e-MycoTM plus Mycoplasma PCR Detection Kit (Intron Biotechnology) 
Eppendorf tubes (0.6 ml, 1.5 ml, 2 ml) 
EVOS Cell Imaging System (Thermo Fisher Scientific) 
EZ DNA Methylation-GoldTM Kits (Zymo Research. Catalogue No. D5005 and D5006) 
Fetal Bovine Serum (FBS) (Sigma-Aldrich) 
Flasks (25 cm2 and 75 cm2) 
FuGENE HD Transfection Reagent (Promega) 
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G418 Sulfate (Geneticin) Thermo Fisher Scientific) 
Geltrex Matrix (Thermo Fisher Scientific) 
GenePrint 10 System (Promega) Catalogue No. B9510  
GENios Microplate Reader (Tecan) 
Haemocytometer (Neubauer) 
High Capacity Reverse Transcription Kit (Applied Biosystems) Catalogue No. 4368813 
Human recombinant Epidermal Growth Factor (HrEGF) (Life Technologies) 
Human TATA-box Binding Protein (TBP) (Applied Biosystems) 
HyperLadder 50 bp (Bioline) 
Microscope 
MTT 3-(4, 5-dimethylthiazol)-2-yl)-2, 5-diphenyltetrazolium bromide (Sigma-Aldrich) 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) 
Nitroblue Tetrazolium Chloride (Thermo Fisher Scientific) 
Oligo 7 Primer Analysis Software (Molecular Biology Insights MBI) 
PCR Machine (Thermo Fisher Scientific) 
pH Strip 
Phosphate Buffered Saline ((PBS) (Sigma Aldrich) 
Polystyrene Cloning Rings (Thermo Fisher Scientific) 
Primer / Probe sets for lncRNAs 
pTARGET Mammalian Vector Expression System (Promega)  
PyroMark Assay Design Software 2.0 (Qiagen) 
PyroMark Binding Buffer (Qiagen) 
PyroMark Q96 Vacuum Workstation (Qiagen) 
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QIAamp DNA Blood Mini Kit (Qiagen). Catalogue No. 51104 
QuantiTect Probe Master Mix (Qiagen) 
Real Time PCR Instrument 7500 & 7500 Fast (Applied Biosystems) 
RNase-free Water (Thermo Fisher Scientific) 
RNaseZAP (Ambion) Catalogue No. 9780 
Safe View Nucleic Acid Stain (NBS Biologicals) 
SOC Media (Sigma-Aldrich) 
Sodium Hydroxide (NaOH) 
Streptavidin Sepharose High Performance Beads (GE Healthcare) 
SurePrint G3 Comparative Genomic Hybridization (CGH) Microarray Platform (Agilent  
Technologies) 
ThinCert Cell Culture Inserts (24 well plate) (Greinier Bio-One) 
Trigene 2% 
Trypsin-EDTA Solution (Sigma Aldrich) 
Tryptone, Yeast Extract, Sodium Chloride (Thermo Fisher Scientific) 
Universal Tubes (25 ml) 
Valproic Acid (VPA) (Sigma-Aldrich) Catalogue No. P4543 
Water Bath 
Well Plates (24, 48 and 96) 







2.2.1. NSCLC Primary Tissues 
All the samples used in this study were obtained from Liverpool Lung Project (LLP) and 
adequate ethical guidelines stipulated by the University of Liverpool ethics committee have 
been adhered to in relation to sample handling, patient consent and confidentialities 
(https://www.ethicsguidebook.ac.uk). 
2.2.2. NSCLC Cell lines and Cell Culture 
Nine (9) NSCLC human cell lines (A549, CALU6, CORL23, SKLU1, CALU3, SKMES, LUDLU1, 
LUNG14 and H358) and four (4) Non-tumorigenic immortalized Human Bronchial Epithelial 
Cells with its isogenic derivatives or variants (KRAS mutation and TP53 knockdown) (HBEC3 
KT, HBEC3 KTR. HBEC3 KTP53 and HBEC3 KTR53) were utilized in this study. An overview of 
the cell lines used, and their histological origin is shown in Table 2.1.  
All cell culture procedures were carried out under sterile conditions in a Class II Biological 
Safety Cabinet (Esco). NSCLC cells were maintained in a humidified incubator with a 
constant supply of 5% CO2 at 37
oC and were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 5% or 10% FBS and F-12 Hams nutrient mixture. All HBECs were 
maintained in Keratinocyte-SFM medium supplemented with 50 μg/mL Bovine Pituitary 
Extract (BPE) and 5 ng/ml human recombinant Epidermal Growth Factor (rEGF). Cells were 
grown in 25 cm2 and 75 cm2 flasks and routinely passaged when monolayer cell growth was 
about 85%-95% confluent.  
For passaging, cells were washed twice with sterile Dulbecco’s phosphate buffered saline 
(PBS), treated with trypsin-EDTA and incubated at 37 °C and 5% CO2 incubator until cells had 
detached from the flasks, after incubation equal volume of medium was added to the flasks 
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to pipet the cells up and down to disperse them. Cells were pelleted by centrifugation at 
300 g for 5 minutes and resuspended with medium and transferred to flasks containing 
fresh medium and incubated at 5% CO2 and at 37
oC. 
All cell lines were tested for mycoplasma using the e-MycoTM plus Mycoplasma PCR 
Detection Kit (Catalogue no. 17341) according to manufacturer’s protocol and authenticated 
using the short tandem repeat (STR) profiling kit and software GenePrint 10 Kit prior to the 
commencement of the study. STR profile obtained for the cell lines was compared with STR 
profile of the same cell lines from https://www.lgcstandards-atcc.org. 
Table 2.1: Cell lines utilized in this study and their histological subtypes (source: ATCC, 
ECACC) 
Cell lines Histological Subtype 
A549 Adenocarcinoma 
CALU6 Adenocarcinoma 
CORL23 Large-cell carcinoma 
SKLU1 Adenocarcinoma 
CALU3 Adenocarcinoma 
SKMES Squamous cell carcinoma 
LUDLU1 Squamous cell carcinoma 
LUNG14 (PC9) Adenocarcinoma 
H358 Bronchioalveolar adenocarcinoma 
HBEC3 KT Non-tumorigenic human bronchial epithelial 
HBEC3 KTR Non-tumorigenic human bronchial epithelial 
HBEC3 KT53 Non-tumorigenic human bronchial epithelial 
HBEC3 KTR53* Non-tumorigenic human bronchial epithelial 




2.2.3. RNA Expression Analysis 
2.2.3.1. RNA Extraction 
RNA extraction was carried out in a laminar flow hood and all materials sterilized with 2% 
trigene and 70% ethanol. Total RNA was extracted using Direct-zol RNA miniprep kit 
following manufacturer’s protocol. Cells grown in a 75 cm2 flask to ~70% confluency were 
aspirated of old medium, washed with 10 ml DMEM PBS twice, lysed with 1 ml TRI-Reagent 
and collected in a 1.5 ml Eppendorf tube. Equal volume (1:1) of absolute ethanol (95-100%) 
was added to the TRI-Reagent and mixed thoroughly by vortexing for 30 seconds. The lysate 
was loaded into a Zymo-Spin™ IIC Column and centrifuged at 16,000 g for 1 minute. The 
column was transferred into a new collection tube and the flow through discarded, for 
lysate volumes more than 700 μl, the column was reloaded with remaining lysate and step 2 
repeated, the column was then transferred into a new collection tube and the flow through 
discarded. DNase treatment was carried out by adding 80 µl DNase I reaction mix (Table 2.2) 
directly into the column and incubated at room temperature for 15 minutes before 
centrifuging for 1 minute. After which, 400 μl of Direct-zol RNA PreWash Buffer was added 
to the column and centrifuged at 16,000 g for 1 minute, this step was repeated. 
Table 2.2: Composition of DNase I Reaction Mix 
DNase I’ (lyophilized) 5 µl 
DNase I Reaction Buffer (10X) 8 µl 
DNase/RNase Free Water 3 µl 
RNA Wash Buffer (with ethanol) 64 µl 
 
700 µl of RNA Wash Buffer was then added to the column, centrifuged for 1 minute at 
16,000 g and the column transferred into a collection tube and centrifuged for 4 minutes at 
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16,000 g in order to discard any residual volume. To elute RNA, the column was transferred 
in a clean 1.5 ml new RNase-free collection tube, 50 µl of DNase/RNase-Free Water was 
carefully added to the column and incubated at room temperature for 1minute. After which 
the column was centrifuged at 16,000 g for 1 minute and the eluted RNA was used 
immediately or stored at -80oC until use. 
2.2.3.2. RNA Quantitation 
Quality control assessment of the RNA samples was carried out to determine their 
concentration, purity and integrity. 
RNA concentration and purity 
The concentration and purity of the RNA samples obtained from NSCLC cell lines were 
determined using the NanoDrop 2000 Spectrophotometer and absorbance measured at 260 
nm and 280 nm. After initializing from the NanoDrop 2000 software and RNA selected as the 
nucleic acid to be measured, the upper and lower optical surfaces of the machine were 
cleaned with RNAse-free water and wiped off using sterile dry lint-free wipes. Blank 
measurement was taken with 1.5 µl of RNAse free-water and the optical surfaces wiped 
clean. 1.5 µl of RNA sample was dispensed unto the lower optical surface, the upper lever 
arm closed and measured. The same procedure was repeated for each individual sample 
and the optical surfaces wiped clean after each measurement. 
RNA integrity 
The concentration and quality of RNA samples from NSCLC tumour and their adjacent 
normal tissues was determined using the Agilent RNA 6000 Nano kit on an Agilent 2100 
Bioanalyzer (a chip-based capillary electrophoresis). Summarily, the bioanalyzer electrodes 
were decontaminated with 400 µl RNaseZAP and DEPC (diethyl pyrocarbonate) water 
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respectively. 550 µl of RNA 6000 gel matrix was vortexed for 1 minute, transferred by 
pipetting into a spin filter, centrifuged at 1,500 g for 10 minutes and aliquots of 65 µl used 
per chip. RNA Gel-dye mix was prepared by adding 1 µl of vortexed RNA dye concentrate to 
65 µl of gel matrix, the mix was vortexed for 30 seconds and centrifuged at 14,000 g for 10 
minutes before use. RNA chip was placed on the chip priming station and 9 µl of gel-dye mix 
was loaded into well marked G on the chip. The gel-dye mix was spread across the channels 
of the chip by pressing down the plunger and holding for 30 seconds, after which the clip 
was released. 9 µl of gel-dye mix was added to the wells marked G, 5 µl of the marker was 
then pipetted into all the wells (including the well designated with the ladder symbol). 1 µl 
of each RNA sample and 1 µl of ladder previously denatured at 70oC for 2 minutes were 
added to each sample well and the well that is marked with the ladder symbol respectively. 
The chip was vortexed for 1 minute at 2400 r.p.m. and placed on the Agilent 2100 
Bioanalyzer to run. RNA samples with RIN values ≥ 8 were selected for microarray. 
2.2.4. Expression Microarray 
Expression microarray profiling was carried out by the Centre for Genomic research (CGR), 
University of Liverpool. The human 8x60k array manufactured by Agilent Technology with 
design ID: 047718 generated by Gencode Consortium (Version 15) and the SurePrint G3 
Human lncRNA chip were used in this study. The array had 2 probes per lncRNA transcript 
and targeted 22,001 lncRNA transcripts and 17,535 randomly selected protein coding 
targets. 
RNA samples from forty-four (44) paired NSCLC tumour tissues and adjacent normal tissues 
obtained from the LLP were reverse transcribed and cDNAs labelled with cy3 (tumour 
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tissues) and cy5 (normal tissues) cDNA probes respectively; and hybridized to a two-colour 
array platform.  
The array data was processed and generated by the CGR, University of Liverpool and then 
analyzed by Dr. Russell Hyde. 
2.2.4.1. Reverse Transcription 
Reverse transcription of RNA samples obtained from tissues and cell lines was carried out 
using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). 2X master mix 
was prepared by mixing 2 µl of 10X Reverse Transcription Buffer, 0.8 µl of 25X dNTP mix 
(100 mM), 0.6 µl of Anchored Oligo (dT) (100 µM), 1 µl of MultiScribe™ Reverse 
Transcriptase (50 U/µl) and 5.6 µl of nuclease-free water. RNA concentration was 
standardized to 1 µg per 20 µl concentration (50 ng/µl). 500 ng RNA to be reverse 
transcribed was denatured by heating at 70ᵒC for 5 minutes and left to cool on ice for 2 
minutes, after which 10 µl of 2X master mix was added to the RNA sample and mixed by 
pipetting and centrifugation. The reaction was performed using a thermal cycler with the 
following conditions: 25oC for 10 minutes, 37oC for 120 minutes, 85oC for 5 minutes and 6oC 
for ∞. cDNAs obtained after reverse transcription were diluted 5X and stored at -20oC for 
further use. 
2.2.4.2. Primer Design 
qRT-PCR primers and probes were designed for lncRNA expression analysis in NSCLC tissues 
and cell lines using primer design software Oligo7 (MBI) (Table 2.3). Primer sets were 
optimized and run on a 2% gel to confirm the appropriate size. 
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2.2.4.3. Quantitative Real Time PCR (qRT-PCR) 
RNA level analyses were carried out for selected lncRNA transcripts chosen from the 
microarray data. qRT-PCR assays were performed using the TaqManTM gene expression 
assays (Applied Biosystems). Expression assays were carried out in a final reaction volume of 
15 μl in duplicates and contained 7.5 μl of 2X QuantiTect Expression Probe Mix (Qiagen), 
0.75 μl of primer/probe mix of my targets (900 nM:250 nM), 0.75 μl TBP (0.70 μl for down-
regulated lncRNAs), 3 µl of cDNA and the remaining volume made up with double distilled 
water (ddH2O). Assay reactions were run on a 7500/7500Fast Thermal Cycler (Applied 
Biosystems) under the following conditions: - 95ᵒC for 15 minutes (activation step), 50 
cycles of 94ᵒC for 15 seconds (denaturation step), varying annealing temperatures and 60ᵒC 
for 45 seconds (extension). RNA levels were expressed as relative quantification (RQ) and 




Table 2.3: Primers and probes designed for validation of lncRNAs discovered through microarray 
lncRNA  Primer Sequence    
  Forward 5’ - 3’ Reverse 5’ - 3’ Probe 5’ - 3’ Ta (oC)1 
Induced FEZF1-AS1 TGGCTATGGTTACTGCAATTC CCATAAAGTCCAACCCTGAGT AAAAGGCCTGTGAGGTGTGTCCC 53 
 
 
LINC01214 GCATACTTCTGGTAGCAATGG TAGGGATTATGTGTCTTCATTCTG ACCTCAAGTCCCCTTTGACCCG 54 
LOC105376287 CACCCTCCTCCACTGTCCT CCTCCTGCTTTGTTTCCTGT TCCCTGCACTAGGTCAGACAATCCC 54 
 PCAT6 ACCCCACTTTCCAGCCTG AGGGAGGCTCACGGACAC CCAGATCTGCAGCCTTCGCCC 55 
 LOC101927229 CTTGACACGACTTCAGAAGCCTC GCAGAGCTCGACCAGGACAG TCTGGCCCATCGTGGCATGGT 58 
 LINC00673 GAAAGGACAAGAAAGAGGATGG AGAGGTGGTCCAGCCTGA TTCCCACCAGGAAGTTTAGCAGAACC 54 
 NUTM2A-AS1 GGCTCATATGACATTAACAGACAA TATCGCCTCCTGTACTATCAAAAT AAGACAGGCAACGTGTTGGACCTTC 54 
 RNF139-AS1 GCGACTGAAGGGCAAGAAC CCAACTTGTGTTTTAGATGAGTCCT CCCATAATGGCCTCTCTCCTTTTGCT 58 
Repressed LANCL1-AS1 GTGAAAGTATTCTCTGACTGCAA TGCATTGGCCAGAACATA TGACCACCTGTCTTTCTATATCAGAACCC 55 
 FENDRR GCTTCTGTCCAAGGCACT CAAGCTTGCTAACTTCTTTGC AGCCTACTCGTCAAAAGCCCGA 55 
 LINC00968 CTACAGCAAGGCAACTTATCTCAC TGGGAGGGAAGGATGACAA TCACCAAGATATTCTGCACTTTCAGTGGC 57 
 SVIL-AS1 ACCTTTGATCCAGAACTTGCAG CTAAGGGGTGGCTGCATTC TCTTCGGTTGTGAATCCGGCCC 59 
 PCAT19 TGTTATTTGGCTGGAGTGAGG AATTCATTCCACTGTAAGCCTTC ATGAGTATCTCCAATGGTTCCCTGTTCTG 60 
 
                                                 
1
 Ta is the temperature at which the single stranded DNA anneal to the template in the RT-qPCR process. 
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2.2.5. DNA Methylation Analysis 
2.2.5.1. Genomic DNA Extraction 
DNA extraction was performed using QIAamp DNA Blood Mini Kit (Qiagen). Medium was 
discarded from the 75 cm2 flasks and the cells were washed with 10 ml PBS twice. 500 µl of 
ATL buffer and proteinase K (stock solution 10 mg/ml) to a final concentration of 100 μg/ml 
were added and the cells were scraped off and transferred in a 2 ml tube. 500 ul of AL buffer 
was added and mixed thoroughly by vortexing and the samples were incubated at 56oC for 
30 minutes, after which 520 μl absolute ethanol was added in a 1:1 ratio and mixed 
thoroughly. The suspension was transferred to an IC spin column and centrifuged at 16,000 
g for 1 minute, the flow-through was discarded and the collection tube was replaced with a 
new one.  700 µl of AW1 buffer (with ethanol) was added to the column, centrifuged for 1 
minute at 16,000 g and flow-through was discarded. This was followed by addition of 680 µl 
of AW2 buffer (with ethanol), centrifugation at 16,000 g for 1 minute and flow-through 
discarded (this step was repeated). The IC spin column was transferred in a new collection 
tube and centrifuged for 4 minutes at 16,000 g to be completely dried out. The column was 
transferred in a 1.5 ml tube and 50 µl of AE elution buffer was added directly to the silica 
membrane, allowed to stand for 5 minutes at room temperature and then centrifuged at 
16,000 g for 1 minute.  The eluted DNA was collected and stored at -20oC for further use.  
2.2.5.2. DNA Quantitation 
The NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific) was used to quantify and 
assess the purity of DNA. The procedure was similar to that of RNA quantitation; however, 
DNA was selected as the nucleic acid to be quantified. Measurement was taken for the 
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quantity of DNA in concentration (ng/μl) and the purity of the DNA samples represented by 
A260/A280 and A260/A230 ratios.   
2.2.5.3. Bisulfite Conversion 
Bisulfite treatment of DNA sample was carried out using the EZ DNA Methylation-GoldTM Kit 
(ZymoResearch) to assess the methylation status of the gene promoters. The CT Conversion 
Reagent was prepared following manufacturer’s protocol. 900 µl of pre-warmed (60oC) 
water, 300 µl of M-Dilution Buffer and 50 µl M-Dissolving Buffer were added to a tube of CT 
conversion reagent. It was vortexed for about 2 minutes and left on the rotating mixer for 
further 8 minutes. 130 µl of the CT Conversion Reagent was added to 20 µl of DNA sample 
(1 µg) in a PCR tube, the samples were mixed by flicking the tube or pipetting up and down, 
and then spun down briefly. Afterwards, they were placed in a thermal cycler under the 
following conditions: - 98°C for 10 minutes, 64°C for 2.5 hours and 4°C storage up to 20 
hours. At the expiration of PCR incubation time, the bisulfite-treated DNA was cleaned up. 
600 µl of M-Binding Buffer was added to 150 μl of bisulphite conversion reaction and mixed 
thoroughly by pipetting in a 1.5 ml tube. The mix was transferred in a Zymo-Spin™ IC 
Column and placed in a collection tube. The sample was centrifuged at 16,000 g for 1 
minute and the flow-through discarded. 200 µl of M-Wash Buffer was added to the column 
and centrifuged at 16,000 g for 1 minute. 200 µl of M-Desulphonation Buffer was added to 
the column and left to stand at room temperature for 20 minutes. Then, the column was 
centrifuged for 30 seconds at 16,000 g. 300 µl of M-Wash Buffer was added to the column 
and centrifuged at 16,000 g for 1 minute. Another 300 µl of M-Wash Buffer was added and 
centrifuged for an additional 4 minutes. The column was placed into a 1.5 ml tube and 50 μl 
of pre-warmed (65oC) M-Elution Buffer was added directly to the column matrix. The 
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column was incubated at room temperature for 5 minutes and centrifuged for 1 minute at 
16,000 g to elute the DNA. The bisulphite converted DNA was stored at -20°C for about a 
week or -70°C until use. 
2.2.5.4. Pyrosequencing Methylation Analysis 
The pyrosequencing technique allows for the detection and quantification of DNA 
methylation at specific CpG sites within a specified region of interest in real time.  The 
protocol involved the preparation of samples, the design of pyrosequencing primers and 
pyrosequencing. 
2.2.5.5. Polymerase Chain Reaction (PCR) 
The methylated DNA samples were amplified by PCR using two amplification primers 
forward biotinylated (Fb) and reverse non-biotinylated (R) in a 1:2 ratio (Table 2.4); and 
performed in a 25 µl volume containing 2.5 µl of coral load buffer, 1 µl of 5 mM dNTP, 1 µl 
of primer mix, 0.125 µl of HotStar Taq polymerase, 3 µl of DNA sample and ddH2O. Thermal 
cycling conditions were set at 95oC for 5 minutes and 40 cycles of 94oC for 30 seconds, 58oC 
for 45 seconds, 72oC for 45 seconds and 72oC for 10 minutes. 
Table 2.4: LINE1 primer used for the evaluation of global methylation analysis 
Primer Name Primer Sequence 5’ – 3’ Modification Tm(oC2) 
LINE1-Fb (Forward) TAGGGAGTGTTAGATAGTGG 5’- 
Biotinylation 
52.1 
LINE1-R (Reverse) AACTCCCTAACCCCTTAC - 51.8 
LINE1-S 
(Sequencing) 
CAAATAAAACAATACCTC -  
 
                                                 
2
 Tm is the primer melting temperature at which 50% of the DNA duplex becomes single stranded. 
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2.2.5.6. Agarose Gel Electrophoresis 
DNA fragments were separated using 2% agarose gel electrophoresis. The gel was prepared 
by dissolving agarose in 0.5X TBE buffer. 1.5 µl of safe view nucleic acid was added to 65 ml 
(2%) agarose solution to visualize the DNA. To load the samples, the DNA was mixed in 
equal volume ratios with the agarose gel loading buffer. Electrophoresis was performed at 
80 V for 60 minutes. DNA was detected using UV light and the size of the DNA was 
determined using 50 bp ladder. Successful bisulfite conversion was seen in the strong bands 
formed after agarose gel electrophoresis separation. 
2.2.5.7. Primer Design 
Prior to primer design, the DNA region of interest of specified length was verified and 
obtained from GeneBank (NCBI), and the primers (forward, reverse and sequencing) used in 




Table 2.5: Pyrosequencing primers sequence of targeted lncRNAs of interest 
lncRNA Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) Sequencing Primer (5’ – 3’) Ta (oC)3 
FEZF1-AS1 TTTTGGGTTTGGTATTAGGA BIO-CCCAAACTCAACTACAACATT GGGTTTGGTATTAGGAG 54 
PCAT6 TTAGTTAAGGGAGTTGATTGGT BIO-CAAACTAAAATTACCCAAATCC GTTGATTGGTAGGTAGT 53 
LINC00673 TATATAAGGGTAGAATGGTTTAGT BIO-CAAAACCACAAATACCAAAAAC GTTTAGTAGATTGTAGGG 51 
NUTM2A-AS1 GGAGGAAGAATGTAGGGAGA BIO-AAACCAACACCAACCAATAA GGGAGATTTTTAGTGGAT 57 
RNF139-AS1 BIO-TATTTTAGGGAGTTTGAAAGT ACCACACCCAACCTAATA CCACACCCAACCTAATACC 52 
FENDRR BIO-TGTTTTTAGGAATTTGGTTTG CCTTAACCTAATACCCCTATAAACTC ACCTAATACCCCTATAAACT 53 







                                                 
3
 Ta is the annealing temperature. 
4




All reagents were allowed to equilibrate at room temperature before use, assay plate layout 
was set up using the PyroMark software and the pre-run information was calculated to 
determine the volume of enzyme, substrate and nucleotides required in the cartridge. 75 μl 
of Binding Mix (made up of 50 μl PyroMark Binding Buffer, 23 μl of ddH20 and 2 μl 
Streptavidin- Sepharose (S-S) beads) was added to 20 μl of PCR product, mixed thoroughly 
and transferred to a 96 well plate. The plate was sealed with adhesive film and agitated on a 
monoshaker for 10 minutes at 350 r.p.m to ensure proper mixing of the S-S beads with the 
PCR products. 45 μl of annealing mix (made up of 43.5 μl PyroMark Annealing Buffer and 1.5 
μl methylation sequencing primer (10 μΜ)) was prepared per sample and placed in 
appropriate wells in a “soft” 96-well plate. The PyroMark vacuum station trough was filled 
with 70% Ethanol, 0.2 M NaOH (denaturation solution), Tris-acetate (pH 7.5) and ddH20. The 
Vacuum tool was turned on and immersed into ddH20 for 30 seconds to allow the water to 
be flushed through the tool and switched off. It was then lowered into the 96 well plate 
containing the PCR products and the S-S beads and mixed gently to allow the samples to be 
attached to the probes. The vacuum tool was washed by immersing into 70% Ethanol, 0.2 M 
NaOH solution and Tris-acetate for 10 seconds respectively and held vertically to allow to 
drain. The tool with the S-S beads and PCR product was lowered directly into the 96-well 
plate containing the annealing mix, and gently agitated to release the beads. The 96 well 
plate was incubated on a heating block (Dri-Block DB-2A) at 80oC for 2 minutes and left to 
cool for 3 minutes at room temperature. The 96 well plate was then transferred into the 

























2.2.6. Decitabine Modulatory Effect on Global DNA Methylation 
5-aza-2-deoxycytidine (Decitabine - DAC) and Valproic Acid (VPA) treatments were carried 
out on 4 NSCLC cell lines (A549, CALU6, H358 AND SKLU1) to assess global DNA methylation. 
3 x 104 cells were seeded in four 12 well plates in triplicate and grown in 500 µl DMEM 
supplemented with 5% FBS. At 70% confluency cells were exposed to 100 nM DAC and 1 
5’--ATACCTATAAC--- 
 3’---    GGA---------- 
DNA polymerase + dNTPs 






dDNPs + dNMPs + Phosphate 
ADP + AMP + Phosphate 
Figure 2.1: Illustration of pyrosequencing principle adapted from Coyler et al. 2012. 
The first nucleotide (dNTPs) is released and if complementary to the template strand, 
it is then incorporated by DNA polymerase, leading to the release of inorganic 
pyrophosphate (PPi) in a quantity that is equimolar to the amount of nucleotide 
incorporated. PPi is converted to adenosine triphosphate (ATP) by ATP sulfurylase in 
the presence of adenosine 5’-phosphosulfate (APS). Luciferase utilizes ATP and drives 
the conversion of luciferin to oxyluciferin, generating visible light in amounts 
proportional to the number of incorporated bases in the sequence, while 
unincorporated nucleotides are degraded by apyrase before the release of another 
base. The light produced is detected by a charge-coupled device (CCD) camera and 
seen as a peak in a pyrogram. 
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mM VPA and incubated at 37°C and 5% CO2 for 48 hours (with medium replenished with the 
drugs in 24 hours). Old medium was vacuumed off, cells were washed with 1 ml PBS, RNA 
and DNA were extracted and stored at -80oC for further use.  Efficiency of DAC and VPA was 
determined by measuring global DNA methylation by pyrosequencing as shown in Section 
2.2.6.4 and Figure 2.1. 
2.2.7. Transfection 
Preparation of Luria Broth (LB) Plates 
LB medium (solid culture) was prepared in a class II cabinet by dissolving 5 g tryptone, 2.5 g 
yeast extract, 5 g sodium chloride (NaCl) and 7.5 g agar in 500ml of ddH2O, autoclaved and 
allowed to cool to 50oC prior to the addition of 100 µg/ml ampicillin. The medium was 
mixed thoroughly, and 20 ml transferred into each 10 cm2 plate, swirled gently and left to 
set at room temperature before storing in sterile films at 4°C for further use. 
Ligation using pTARGET Vector _ LINC00968 
The pTARGET mammalian vector expression system purchased from Promega was used in 





Figure 2.1: pTarget_968 vector. Figure extracted from SnapGene. 
 
2.2.8. Transformation  
Eschericia coli competent bacteria used for transformation was stored at -80°C prior to use. 
An aliquot of 50 μl E. coli competent bacteria was allowed to thaw on ice and 1 µl of DNA 
was added and incubated on ice for 30 minutes. The cells were subjected to heat shock by 
incubating in the water bath at 42°C for 30 seconds and returned to ice for 2 minutes. 900 µl 
of pre-warmed SOC medium was added to the cells and incubated at 37°C for 1 hour in a 
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shaking incubator. 200 μl of the reaction mix was spread onto each LB plate containing the 
ampicillin and incubated overnight at 37°C. 
2.2.8.1. Plasmid DNA Extraction 
Plasmid DNA was extracted using the Zyppy Plasmid Midiprep Kit (ZymoResearch) following 
manufacturer’s protocol. Summarily, 6 ml of bacterial culture in LB medium was transferred 
into a 25 ml falcon tube, 1 ml of 7X lysis buffer (blue) was added to the culture medium and 
mixed by inverting the tube 2 - 4 times and left to sit at room temperature for 2 minutes. 5 
ml of neutralization buffer (yellow) was then added gently to the mixture and inverted 4 - 6 
times until a homogenous mix was achieved and the tube placed on ice for 5 minutes. The 
mixture was transferred into the Zymo-Midi Filter/ Zymo-Spin column assembly placed on a 
vacuum manifold and the vacuum switched on to allow the liquid to flow through. The 
Zymo-Spin column was transferred to a collection tube and centrifuged at >11,000 g for 30 
seconds to remove all traces of the lysate. 400 µl of Endo-Wash Buffer was added to the 
zymo-spin column and centrifuged at >11,000 g for 30 seconds, this was followed by 
addition of 400 µl of Zippy Wash Buffer and centrifuged at >11,000 g for 30 seconds. The 
zymo-spin column was finally transferred to a 1.5 ml microcentrifuge tube and 150 µl of pre-
warmed (65oC) Zyppy Elution Buffer added directly to the centre of the tube and centrifuged 
at >11,000 g for 1 minute. Eluted plasmid DNA was quantified and dried out at 65oC for 30 
minutes and stored at -20OC for further use. 
2.2.8.2. G418 (Geneticin) Kill Curve 
To use G418 as a selection marker, the optimal working concentration was determined by 
carrying out a kill curve. A549 cells were plated in triplicate in 800 μl DMEM supplemented 
with 5% FBS and 10X Penicillin-Streptomycin (pen-strep) per well in a 24 well plate and 
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incubated at 37oC until 70% confluent. Cells were then exposed to varying concentrations 
(400 - 900 µg/ml) of G418 including control and observed for 7 days (with replacement of 
media/G418 every 48 hours). 
2.2.8.3. Stable Transfection with pTarget_968 
A549 cells were transfected using the FuGENE HD Transfection Reagent following 
manufacturer’s protocol. 20 µg of Plasmid DNA was resuspended in 100 μl of sterile ddH20, 
mixed by vortexing and incubated at 4oC overnight. A549 cells were seeded at a very low 
density in a 10 cm2 dish to achieve 50% confluency before transfection. At 50% confluency, 
the old medium was vacuumed off, the cells were washed with 10 ml PBS and replaced with 
8 ml DMEM supplemented with 5% FBS and 10X Pen-Strep. Cells were transfected with the 
transfection reagent mix (Table 2.6) dropwise into the dish for even distribution and 
incubated at 37°C and 5% CO2 for 24 hours. 
Table 2.6: Transfection Reagent Mix 
Reagent/ Sample Volume Reagents were mixed in a 
tube, vortexed, spun 
briefly and incubated for 7 
minutes at room 
temperature before use. 
 
 
Plasmid DNA (4 µg) 20 μl 
DMEM + FBS 368 μl 
*FuGENE HD 12 μl 
Total 400 μl 
 *FuGENE to plasmid DNA ratio was 3:1 
After 48 hours, the cells were washed with 10 ml PBS and 8 ml DMEM containing 2.5% FBS, 
10X Pen-Strep and 700 µg/ml G418 was added to select the resistant clones (this process 
was repeated until single clones were formed). 12 single clones were isolated using sterile 
polystyrene clone rings, trypsinized with Trypsin-EDTA and 2.5% FBS, transferred to a 
properly labelled 24 well plate and incubated for 24 hours. Following which, the clones were 
maintained with DMEM containing 5% FBS, 10X pen-strep and 500 µg/ml G418. The clones 
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were further harvested and grown in 25 cm2 and 75 cm2 flasks respectively for expansion 
and further use. Successful transfection was confirmed by qRT-PCR as shown in Section 
2.2.4.3. 
2.2.9. Phenotypic Analysis 
2.2.9.1. MTT Assay 
The viability of the A549 parent cell line and overexpression derived clones were measured 
using the MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. A549-
LINC00968 cell clones and A549 parent cell line were counted and 30,000 cells plated per 
well in a 48-well plate and incubated for 24 hours at 37oC and 5% CO2. After incubation 
period, the medium was vacuumed off and the cells washed with PBS. Fresh medium 
containing 0.75 mg/ml MTT was added to the cells and incubated for up to 4 hours at 37°C 
and 5% CO2, until purple formazan crystals are visible under a microscope. Medium 
containing MTT was then vacuumed off and cells were solubilized by addition of 200 µl/ well 
of equimolar ratios of DMSO and isopropyl alcohol, and incubated at 37°C for 2 hours, until 
cells have lysed and purple crystals have dissolved. Absorbance was measured at 595 nm 
with 630 nm as reference using a GENios Microplate Reader at 8, 24, 48, 72 and 96 hours 
respectively. 
2.2.9.2. Soft Agar (Anchorage Independence) Assay 
The soft agar assay made up of a top and a base layer of soft agar was used to monitor 
Anchorage-Independent Cell Growth. The base layer was prepared by mixing 1% agarose 
(Noble Agar) and 2X DMEM containing 10% FBS, while the top agar layer was prepared by 
dissolving 0.6% agarose (Noble Agar) in 1X DMEM supplemented with 10% FBS (both agar 
solutions were sterilized by autoclaving before use). A549_LINC00968 cells were counted 
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and 3 x 104 cells from each A549_LINC00968 clone were added to the top agar mixture and 
plated in a 10 cm2 dish and incubated at 37°C for 21 days. Cells were washed with 10 ml PBS 
(Sigma-Aldrich), colonies stained with 200 μl of nitroblue tetrazolium chloride (Thermo 
Fisher Scientific) and counted. 
2.2.9.3. Wound Healing Assay 
The wound healing assay also called the scratch assay was employed to determine 
LINC00968 involvement in cell migration and interaction. Selected A549_LINC00968 clones 
and the A549 parent cell line were plated in 24 well plates and incubated at 37°C and 5% 
CO2 until confluent as a monolayer. A cross-shaped scratch (like a wound) was made on the 
cell surface area at an angle of 30oC using a p200 pipette tip and the wells washed gently 
twice with 1 ml DMEM to remove detached cells. Fresh medium was added, the location of 
the scratch was marked at the bottom of the 24 well plate as reference point, and the 
migration rate of the cells was monitored and quantified using the EVOS Cell Imaging 
System at 0 hours and subsequent intervals. 
2.2.9.4. Boyden Chamber Assay 
The invasive potentials of some selected A549_LINC00968 clones and the A549 parent cell 
line were studied using an adaptation of the Boyden Chamber Assay involving the use of 
ThinCert Cell Culture Inserts (24-well plate) and GeltrexTM matrix. For the invasive study, 
Geltrex matrix was allowed to thaw and mixed by pipetting up and down gently. 100 μl of 
the Geltrex matrix was used for coating each ThinCert Cell Culture chamber and incubated 
at 37oC and 5% CO2 for 60 minutes for gelling. 200 µl of 2 x 10
4 cells maintained in serum-
free DMEM medium were seeded into each ThinCert Cell Culture chamber, transferred into 
a 24-well plate containing 750 µl of DMEM supplemented with 5% FBS and incubated for 16 
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hours at 37oC and 5% CO2. Following incubation, medium was discarded and the chambers 
were washed with PBS, fixed with 70% ethanol and washed with PBS before staining with 
0.2% crystal violet. Non-invasive cells were cleaned off with a cotton swab and invasive cells 
visualized and counted using the EVOS Cell Imaging System.  Same protocol was applied for 
the cell migration study (without the Geltrex coating in the ThinCert Cell Culture chambers). 
2.2.9.5. Oxidative Stress Analysis 
A549_parent cell line and the selected A549_LINC00968 clones were subjected to varying 
concentrations of Hydrogen Peroxide and cell survival measurement taken after 24 hours 
using the MTT assay. 
2.2.9.6 Drug Treatment Assay 
Select anti-cancer drugs used currently in NSCLC therapy were tested on A549_LINC00968 
clones and the parent cell line, and their response monitored. A549_LINC00968 clones and 
the A549_parent cell line were maintained in culture as stated above (2.2). 2 x 103 cells 
were seeded into 48 well plates in DMEM supplemented with 5% FBS and Pen-Strep and 
incubated at 37oC and 5% CO2 until cells were 70% confluent, carried out in 4 technical 
replicates. The old medium was discarded and replaced with new medium containing the 
compounds of interest. After 72 hours of exposure to the drugs, cell survival was measured 
via MTT assay as stated in Section 2.2.9.1.  
2.2.10. Data Interpretation and Statistical Analyses 
All statistical analyses were carried out using SPSS v24.0 (IBM, USA). The qRT PCR results 
were quantified as fold change between TBP and target lncRNAs using the RQ formula 2^-
∆∆CT. The Wilcoxon Signed-Rank non-parametric test for paired samples was used for analysis 
of the target lncRNA expression in NSCLC tumour compared to normal tissues, while the 
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association between the expression of target lncRNAs and the clinicopathological 




3. DISCOVERY AND VALIDATION OF DEREGULATED lncRNA TRANSCRIPTS IN 
PRIMARY NSCLC TISSUES 
3.1. Introduction 
lncRNAs have been implicated in the development and progression of cancer, with a recent 
study reporting a total of 19,175 potentially functional lncRNA genes in the human genome 
(Hon et al., 2017). The urgent need for the development of biomarkers for the early 
detection of NSCLC and the need for novel drug therapies to combat the high mortality rate 
of lung cancer has led to this current investigation.  
3.2. Bioinformatic Analysis 
At the beginning of the study and prior to our own microarray analysis, we carried out a 
bioinformatics analysis involving gene ontology and pathway analysis in order to identify 
lncRNAs with high frequency of deregulation in lung cancer. Data was sourced from publicly 
available databases such as Oncomine and The Cancer Genome Atlas (TCGA) databases 
(overseen by my 3rd supervisor, Dr. Russell Hyde). 
The analysis showed 13 transcripts (lncRNAs and pseudogenes) deregulated in NSCLC. We 
attempted to validate this result by RT-qPCR analysis of COL6A4P1 (DVWA/344875) and 
LINC00669 (LOC647946) transcripts in 48 paired lung samples obtained from the Liverpool 
Lung Project (LLP) Biobank. COL6A4P1 transcripts were significantly overexpressed in lung 
tumour samples compared to their adjacent normals (Wilcoxon’s test p< 0.001), expression 
studies for LINC00669 were inconclusive. Results obtained for COL6A4P1 when compared 
with histological and clinicopathological data showed no significant difference between 
histology subtypes, differentiation and tumour/nodal status(See Appendix I & II) Both the 
LINC00669 and COL6A4P1 were however, not identified in our microarray analysis. 
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The first objective of this study was to evaluate the transcript levels of novel lncRNAs in 
primary NSCLC tissues in comparison to adjacent normal tissues and explore their biomarker 
potential. To achieve this objective, we carried out a microarray analysis to identify novel 
lncRNAs in NSCLC, we then examined the levels of these transcripts in NSCLC tumour and 
normal tissues by qRT-PCR and further explored the correlation of the levels of these 
transcripts with the clinicopathological parameters of the patients.   
3.3. Microarray Analysis 
To identify novel lncRNAs deregulated in NSCLC tissues, RNA samples obtained from a set of 
44 paired NSCLC tumour and adjacent normal samples provided by the LLP were screened 
for their quality. We carried out RNA quantitation and bioanalysis to select RNA samples 
with high RIN (RNA Integrity Number), before samples were sent for Microarray. 
Bioinformatic analysis was undertaken by Dr. Russell Hyde and the raw data was analysed 
using the limma (linear models for microarray) package (Ritchie et al., 2015). 
The two elements considered in the selection of the lncRNAs in this study were the 
consistency of the difference in each lncRNA in the tumours (expressed as the pValue) and 
the actual magnitude of the differences (log fold change).  Following the array analysis, 20 
induced and 30 repressed lncRNAs were identified. (Appendix III and IV).Using Ensembl and 
NCBI BLAST (Basic Local Alignment Search Tool), we further selected   13 lncRNAs with > 
80% homology (sequence similarity), and designed primers and probes for further analysis. 
Selected lncRNA transcripts discovered to be deregulated from the microarray analysis are 




Table 3.1: Selected top deregulated RNAs identified by microarray 
lncRNA  Target ID (Ensembl) *Probe sequence on microarray 5’ – 3’ 
Induced 
FEZF1-AS1 ENST00000428449.1 CACGGTTCGACTGTTTCCTTGACACTACCCACGAAGTTTAAAGCATTTTTTATGTTATTT 
  GAAACAAGCAGACACACACACAAAACAACCATATTCAAGACACGGTTCGACTGTTTCCTT 
LINC01214 ENST00000471222.2 ACTTGAGGTTATCAGCTTTCAGAATGAAGACACATAATCCCTATTAGAGTGGAAGACTTA 
  ATGGGGACACGGGTCAAAGGGGACTTGAGGTTATCAGCTTTCAGAATGAAGACACATAAT 
LOC105376287 (HMGA1P4) ENST00000428643.1 TTTGTCCCAGCCTGGGGCTCCCCCTCTGGTTTCCTATTTGTAGTTACTAGAATGAAAAAA 
  GTTTGTCCCAGCCTGGGGCTCCCCCTCTGGTTTCCTATTTGTAGTTACTAGAATGAAAAA 
PCAT6 ENST00000425295.1 TATTTTGTGTAGTCCTACAACGTCTTGTTACTACCCCCTATTACAACACTTATAACTCAG 
  TTATTTTGTGTAGTCCTACAACGTCTTGTTACTACCCCCTATTACAACACTTATAACTCA 
LOC101927229 (592405) ENST00000592405.1 CCAGATCACTTCTGCATAAAACCACATGGAAGAATAAGAAGGGAAAAACAATCAAGCAAT 
  ACCAGATCACTTCTGCATAAAACCACATGGAAGAATAAGAAGGGAAAAACAATCAAGCAA 
LINC00673 (LINC00511) ENST00000580948.1 CCTCTTGAGAGGCAGGAGCTCTGGATTTGATCAAGAATTCTTTGCTGAGCATGGTGCCTC 
  CTCTTGAGAGGCAGGAGCTCTGGATTTGATCAAGAATTCTTTGCTGAGCATGGTGCCTCA 
NUTM2A-AS1 ENST00000413722.1 AGACTTGGACCGATGCTTGCATTTGTTTCTGAGAATTAAACGTTATGTTTTCTTCAATCC 
  TGACAAAGGTTTGGGAAGGAAGACTTGGACCGATGCTTGCATTTGTTTCTGAGAATTAAA 
RNF139-AS1 ENST00000519861.1 GAGGAGATAGGTGAGTACTATTATATTATGTTCATGGAAAATGAGTTCATGGGCTTTCCT 
 ENST00000530778.1 AGGAGATAGGTGAGTACTATTATATTATGTTCATGGAAAATGAGTTCATGGGCTTTCCTC 
Repressed 
LANCL1-AS1 ENST00000420418.1 TGAAAGTATTCTCTGACTGCAAGTATGACCACCTGTCTTTCTATATCAGAACCCAAGCTA 
  GTGAAAGTATTCTCTGACTGCAAGTATGACCACCTGTCTTTCTATATCAGAACCCAAGCT 
FENDRR ENST00000595886.1 TAAAAATGCTAGAAGCTTTAGTCATAGAATTACCATATGATACAGCCTACTGCAGAGTCC 
  GGCTCTGTTTCATGCTGACTTTACCATCATGTAAGCAGTTTTAAAAATGCTAGAAGCTTT 
LINC00968 ENST00000499425.1 TAACTTCATAAGAAAATGATAAGAAAAATGTGGTCACCGGTATCATGAGGAACTTCCAGA 
  CAACTTGCAGACAGGCAAGAATTTGGCTTTGTATGTTTAAAAATATGTACATCTTGGTTC 
SVIL-AS1 ENST00000446807.1 TGCTTTGGAATCTGGCATTTATGTTTTGAAGCGTTGTGAGCAAGCGATGTGGCAGATTGC 
  TTGAAAGGGCTCTTGGTTTCTGCTTTGGAATCTGGCATTTATGTTTTGAAGCGTTGTGAG 
PCAT19 ENST00000594315.1 ACAAAAATAAAGTGTTATTTGGCTGGAGTGAGGTCTCATGTCTGCTTATGCGGTGGCTCG 
  TACAAAAATAAAGTGTTATTTGGCTGGAGTGAGGTCTCATGTCTGCTTATGCGGTGGCTC 
 *Probe sequence is specific for the different ProbeID not shown in the table. Letter Cs in red indicate methylated cytosines.
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3.4. Validation of Deregulated Transcripts in NSCLC Tumour and Normal 
Tissues 
The 13 lncRNAs identified from the microarray analysis in the discovery phase where 
validated by qRT-PCR in a total of 67 NSCLC tumour and adjacent normal tissues. The 67 
samples were made up of 29 tumour and normal paired samples taken from  the 44 samples 
hybridized in the microarray (termed “technical validation set”), and 38 samples were from 
an independent set of frozen tumour and normal paired samples from NSCLC patients 
(termed “the biological validation set”) (Table 3.2). RNA was extracted from the samples and 
reverse transcribed as described in Section 2.2.3. Primers and probes were designed for the 
different induced and repressed lncRNAs respectively and RT qPCR performed as shown in 
Section 2.2.4.3. 
Table 3.2 Clinicopathological data of patients used for expression analysis of discovered 
lncRNAs 
  Technical set Validation set Total 
N 29 38 67 
Age 
mean (s.d.) 66.4 (8.5) 67.6 (8.4) 67.1 (8.4) 
Gender 
Male:Female 21:8 29:9 50:17 
Histology 
Adenocarcinoma 14 12 26 
Squamous cell 
carcinoma 
15 24 39 
Other - 2 2 
Tumour stage 
T1 1 4 5 
T2 21 30 51 
T3 5 3 8 
T4 2 1 3 
Nodal stage 
N0 15 19 34 
N1 9 12 21 
N2 5 7 12 
Differentiation 
1 8 9 17 
1.5 1 2 3 
2 17 16 33 
2.5 - 2 2 
3 3 4 7 




A total of 67 patient samples were used (of which 29 were from the discovery set and 38 for 
the biological validation set, as earlier stated). The mean age was 66.7 years. 74.6% of the 
patients were males and 25.3% were females. In the technical validation set, equal numbers 
of adenocarcinoma (14) and squamous cell carcinoma (15) subtypes were observed, while 
adenocarcinomas were less than the squamous cell carcinoma subtype in the biological 
validation set (12 and 24 respectively). Most of the samples were shown to be resected at 
stage IB and IIA based on the TNM staging (8th edition Detterbeck et al., 2017), however, 
this was as a result of the amount of T1 samples made available by the pathologists. 17 out 
of the total 67 patient samples were well-differentiated tumours, while 33 and 7 were 
moderately and poorly differentiated respectively. Information about differentiation for 5 
patients in the validation set was missing.  
From our findings, 8 out of the 13 lncRNAs qualified in the microarray analysis as 
upregulated, were significantly elevated in lung tumours compared with paired normal 
tissues both in the technical and biological sets (Figure 3.1 – Figure 3.4). FEZF1-AS1 was 
identified as upregulated in the microarray analysis; interestingly, validation by qRT PCR also 
showed significant elevation of FEZF1-AS1 in NSCLC tumour tissues when compared to the 
corresponding normal tissues in both the technical and the biological validation sets (p= 4.8 
x 10-6 and 6.6 x 10-7 respectively Figure 3.1). Increased levels of LINC01214 can be observed 
for tumours in both sample sets (p= 5.9 x 10-6 and 2.63 x 10-6 Figure 3.1). No significant 
difference was observed in LOC105376287 levels in NSCLC tumours and adjacent normal 
tissues (p= 0.754 and 0.765, Wilcoxon Signed-Rank test Figure 3.2). PCAT6 was significantly 
upregulated in tumours compared to normal tissues (p=2.56 x 10-6 and 5.26 x 10-6 Figure 
3.2). LOC101927229 levels was shown to be induced in tumour tissues in comparison to 
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adjacent normals (p=0.018 and 0.032 Figure 3.3). There was a significant difference in 
LINC00673 levels in NSCLC tumours compared to the normal tissues (p=3.17 x 10-6 and 8.30 
x 10-6 Figure 3.3). NUMT2A-AS1 was upregulated in tumours compared to normal tissues 
(p=0.004 and 0.008 respectively for technical and biological validation sets Figure 3.4). There 
was no significant difference in the expression of RNF139-AS1 in tumours compared to the 
normal tissues in the technical validation set (p=0.325), however, it seemed to be 







Figure 3.1: Levels of identified upregulated lncRNA FEZF1-AS1 and LINC01214 following RT qPCR analysis. FEZF1-AS1 level in 
tumours compared to adjacent paired normals is shown to be significantly upregulated both in the technical validation (TV) sets 
and the biological validation (BV) sets (n=67) p-Values less than 0.05 were considered significant and were derived from Wilcoxon 
signed-rank test.  
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Figure3.2: LOC105376287 though identified as upregulated in the microarray analysis, did not show significant 
difference between the tumours and paired normals both in the TV and BV sets. PCAT6 levels were shown to be 
significantly elevated in lung tumours compared to paired normal tissues both in TV and BV sets. (n=67), with p-values 
less than 0.05 considered as significant and derived from Wilcoxon signed-rank test. 
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Figure3.3: LOC101927229 and LINC00673 levels are shown to be significantly upregulated in tumours compared to 
paired normal tissues both in the TV and BV (n=67)(Wilcoxon signed=rank test). 













































T e c h n ic a l v a lid a t io n
B io lo g ic a l v a lid a t io n
p = 0 .0 1 8 p = 0 .0 3 2







































T e c h n ic a l v a lid a t io n
B io lo g ic a l v a lid a t io n
p = 3 .1 7 x 1 0
-6
p = 8 .3 0 x 1 0
-6
LOC101927229 LINC00673 





Figure 3.4:  Scatterplot graph showing NUTM2A and RNF139-AS1 levels in tumours compared to adjacent paired 
normals. A significant upregulation can be observed in NUTM2A levels in both TV and BV sets, and in TV sets of 
RNF139-AS1. (n=67, p value 0f 0.05 considered as significant).  
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The levels of the repressed lncRNA transcripts that were discovered were also validated in 
the same technical and biological validation sets. All the selected lncRNAs identified as 
repressed, were significantly reduced in tumours compared to paired normal tissues (Figure 
3.5 – 3.7).  
LANCL1-AS1 was significantly downregulated in tumours compared to paired normal tissues 
in both technical and biological validation sets, with p=2.56 x 10-6 and p=1.14 x 10-7 
respectively Wilcoxon signed-rank test (Figure 3.5). Expression of FENDRR was repressed in 
tumours in both validation sets as shown in Figure 3.5 (Wilcoxon Signed-Rank Test p= 2.56 x 
10-6 and 4.54 x 10-7). This result is consistent with the findings from the microarray analysis 
shown in Table 3.1.  Similar results were observed for SVIL-AS1 and PCAT19. Both genes 
were also significantly downregulated in tumour tissues compared to paired normal tissues 
(Figure 3.6 and 3.7). LINC00968 was found to be downregulated in tumours compared to 
the paired normal and this was observed both in the technical and biological validation sets 





   
Figure 3.5: Scatter plot showing significant downregulation of repressed LANCL1-AS1 AND FENDRR following RT-qPCR 
analysis both in the TV and BV sets. p values less than 0.05 were considered significant and were derived from 
Wilcoxon signed-rank test. 
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Figure 3.6: Repressed lncRNAs LINC00968 and SVIL-AS1 are shown to be significantly downregulated in tumours 
compared to adjacent paired normal tissues in the TV and BV sets following RT-qPCR analysis. P values were derived 
from Wilcoxon signed-rank test. 





Figure 3.7: PCAT19 is shown to be also significantly 
downregulated in tumour tissues compared to adjacent paired 
normal tissues in TV and BV sets. p values less than 0.05 
considered significant (Wilcoxon signed-rank test). 
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3.5. Clinicopathological Correlation with Discovered lncRNAs Expression  
The clinicopathological parameters (age, gender, histology subtype, TNM stage and degree 
of differentiation) of the patients were analysed using SPSS v24 and the levels of identified 
lncRNA transcript was correlated with patient clinicopathological characteristics using the 
Mann-Whitney’s test. There were no significant differences in the clinicopathological 
parameters of patients in the discovery set and the validation set, hence both were 
combined to increase our study power.  The levels of all validated lncRNAs were 
independent of age and histology, however, FEZF1-AS1 was observed to be elevated in 
males compared to females (Mann Whitney’s Test, p=0.03).  
We also found that LINC00968 levels were significantly higher in patients with lymph node 
involvement (N1 or N2 stages when compared to N0), while the opposite relationship was 
found for LOC101927229 (Table 3.3). Additionally, both PCAT6 and LANCL1-AS1 showed 
significant difference between the tumour grades (PCAT6 and LANCL1-AS1 levels were 
significantly lower in well-differentiated tumours when compared to poor or moderately 
differentiated ones (Table 3.3). 
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Male 6.49 8.31 1.03 3.66 8.47 
268 0.03 















N(-) 31.63 74.00 4.59 9.05 17.79 
339 0.05 
N(+) 8.00 7.39 3.75 5.01 9.29 
LINC00968 
N(-) 0.20 0.50 0.00 0.00 0.00 
435 0.03 












Well 2.03 3.85 0.50 0.73 1.96 
212 0.02 
Poor-Mod 3.60 5.83 0.82 2.04 3.16 
LANCL1-AS1 
Well 0.02 0.05 0.00 0.00 0.00 
262 0.01 





3.6. Profiling NSCLC cell lines for expression of identified lncRNAs 
Profiling of the levels of identified lncRNAs was carried out in 9 NSCLC cell lines, and 
HBEC3KT and its isogenic derivatives by qRT PCR, to select cell lines suitable for downstream 
genetic manipulation. A representation of the levels of some of the lncRNAs in the different 
cell lines is shown in Figure 3.8 and 3.9. The levels of the selected lncRNAs were variable in 
the lung cancer cell lines. FEZF1-AS1 was high in SKLU1 and LUDLU1, moderate in CALU3 and 
H358 but was not detectable in A549, CALU6, LUNG 14 and the HBECs. Although LINC01214 
was upregulated in NSCLC tumours, interestingly its level was observed to be high in H358 
only, and present at low levels in all other NSCLC cell lines and the HBECs. LOC105376287 






Figure 3.8: Bar chart showing the level of upregulated lncRNAs FEZF1-AS1 and LOC101927229 in NSCLC cell lines, HBEC3KT and its isogenic 
derivatives (HBEC3KT 53, HBEC3KT R and HBEC3KT R53). Red arrow indicates reference cell line for calculation of relative quantity (RQ=1), For 
FEZF1-AS1, SKLU1 was used as the reference since its level was undetected in HBEC3KT. Error bars represent 95% confidence interval (CI). 








Figure 3.9: Bar chart showing the level of validated lncRNAs, PCAT6 and LINC00673 in NSCLC cell lines and HBEC3KT with its isogenic 





The high mortality rate of NSCLC and the persistently low 5-year survival rate for decades 
has been the basis for the search for biomarkers for the early detection of the disease and 
for the discovery of novel therapeutics (Chheang & Brown, 2013; Cancer Research, 2016). 
The relatively recent discovery of the lncRNAs has added a new level of understanding in 
disease pathogenesis as well as a new pool of candidate biomarkers. 
 This study aimed, through a discovery and validation process, to identify lncRNA transcripts 
that are deregulated in NSCLC and which could serve as potential biomarkers using the 
microarray technology and validating the data obtained by RT-qPCR. The microarray 
technology first described about two decades ago (Kononen et al., 1998), has been a reliable 
tool in the study of genetic alterations in cancer and has been instrumental in the 
identification of potential biomarkers for the early detection of cancer (Giltnane & Rimm, 
2004; Holgersson et al., 2010).  
Following microarray analysis in our study, 50 lncRNA transcripts that are deregulated in 
NSCLC (20 highly upregulated and 30 highly downregulated) were identified in tumour 
tissues in relation to their paired normals (P<0.05). 13 transcripts across different p-values 
and fold-changes were selected for validation by RT-qPCR. BLAST searching and optimization 
of primers and probes enabled the identification of all transcripts. Previously incorrectly 
annotated lncRNAs (as in the case of LOC105376287: originally annotated as HMGA1P4 in 
the microarray, LOC101927229: Assay 592405 and LINC00673: originally annotated as 
LINC00511) were recovered (Table 3.1). 
Several studies have previously demonstrated that lncRNAs are differentially expressed in 
tumours compared to normals. Xu et al, in their study, identified 2420 lncRNAs that were 
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differentially expressed between lung adenocarcinomas and normal tissue samples, with 
1213 of the 2420 upregulated and 1207 lncRNAs downregulated. In another study 47 
lncRNAs were shown to be differentially expressed in tumours (14 upregulated and 33 
downregulated) from gene expression data of five NSCLC cohorts that were deposited in the 
Gene Expression Omnibus (GEO) database (Xu et al., 2014; Yang et al., 2014). A larger 
number of lncRNAs were differentially expressed in the study carried out by Xu et al, while 
Yang et al identified a similar number of lncRNAs that were differentially expressed as 
shown in our study. The targets identified by Xu et al and Yang et al differ from those 
identified in our study, and may be related to the difference in the microarray platforms and 
probe used in the different studies. Results obtained by Xu et al, are based on differential 
expression between lung adenocarcinoma and normal tissue samples, while our studies 
involved both lung adenocarcinoma and lung squamous cell carcinoma.  
The transcript FEZF1-AS1 (FEZF1 antisense 1) shown to be upregulated both in the array 
analysis and qRT PCR, is a non-protein coding gene located antisense to the FEZF1 (FEZ 
family zinc finger 1) gene on chromosome 7q31.32, with a transcript size of 2653 bases. 
FEZF1-AS1 was first identified in studies carried out by Ota et al., in 2004, it has been 
reported to be upregulated in human primary colorectal carcinoma and to facilitate cell 
proliferation and migration in colorectal carcinoma. It has also been implicated in gastric 
cancer by its repressive activity on CDKN1A expression, and also identified among the top 50 
genes highly expressed in human invasive mucinous adenocarcinoma (IMA) of the lungs (Liu 
et al., 2017). He et al., in their study, showed that FEZF1-AS1 was upregulated in NSCLC 
tissues, and that downregulation of FEZF1-AS1 inhibited cell proliferation and cell invasion 
(He et al., 2017). FEZF1-AS1 was upregulated in NSCLC tumours and these high levels 
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correlated with sex in our study. FEZF1-AS1 was evaluated in a panel of NSCLC cell lines and 
found to be upregulated in CALU3, CORL23, H358, LUDLU1 and SKLU1 (Figure 3.2A).  
Our findings revealed that LINC01214 (long intergenic non-protein coding RNA 1214) is 
upregulated in tumours in the array analyses as well as in the validation sets (p< 0.05). Its 
expression was reported to be repressed in studies involving the dual inhibition of TNKS and 
MEK in the SW480 KRAS-mutant colorectal cancer cell line, however, expression level of 
LINC01214 in NSCLC has never been reported. LINC01214, an uncharacterized lncRNA is 
genomically located on chromosome 3q25.1, spanning 150265407 to 150323747 bp. The 
amplification of the distal portion of this chromosomal region in lung cancer has been 
shown to be a major indicator of neoplastic transformation, is found in early stages of lung 
cancer development and maintained throughout the progression of cancer until metastatic 
stages (Qian and Massion, 2008). Amplification on chromosome 3q25–3q26 associated with 
a preinvasive lesion that progressed to a subsequent carcinoma has also been described 
(Foster et al., 2005). There may be the possibility of a link between this genetic mechanism 
and LINC01214 expression in NSCLC (You & Jones, 2012). 
LOC105376287 located on chromosome 9q34.11 showed no significant upregulation in the 
discovery set, and validation by qRT PCR confirmed this finding. Therefore, LOC105376287 is 
not upregulated in NSCLC tumours in comparison to the normal tissues in this study. 
However, it is elevated in 2 lung cell lines (H358 and LUDLU1).  
PCAT6 (prostate cancer associated transcript 6) also known as KDM5B/KDM5B-AS1 an 
oncogenic lncRNA located on chromosome 1q32.1, was shown to be induced in both sample 
sets in this study and in 3 NSCLC cell lines (CALU3, CORL23 and LUNG14). This finding is 
consistent with studies carried out by Wan et al, which showed significant increase in PCAT6 
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expression in lung cancer tissues when compared to normals, and in lung cancer cell lines 
compared to normal human bronchial epithelial cells. Knockdown of PCAT6 was associated 
with inhibition of cell proliferation and metastasis (Wan et al., 2016). 
LOC101927229 was upregulated in NSCLC tumours compared to adjacent normals in this 
study. There has been no published information on this lncRNA target. It was shown to be 
high in LUNG14, moderate in LUDLU1 and was not detectable in CALU3 and SKMES. 
LINC00673 was upregulated in this study, and its high level correlates with previous studies. 
Shi et al reported an upregulation of LINC00673 expression in their study, following 
bioinformatic analyses and qRT PCR in NSCLC (Shi et al., 2016). They further demonstrated 
that knockdown of LINC00673 was associated with inhibition of cell proliferation and ability 
to form colonies. LINC00673 has also been reported to regulate NSCLC proliferation, 
migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p (Lu et al., 
2017). It has been shown to promote metastasis in NSCLC by binding to EZH2 resulting in 
epigenetic silencing of HOXA5 which is known to regulate gene expression (Ma et al., 2017). 
NUTM2A-AS1 levels were shown to be elevated in this study. It is located on chromosome 
10q23.2 of the cytogenic band, on the opposite strand of the NUTM2A gene. Studies have 
linked chromosome 10q21 – 10qter to genetic susceptibility to loss of heterozygosity (LOH), 
and showed a link between LOH and advanced tumour stage in LSSC (Petersen et al., 1998). 
NUTM2A-AS1 is among a sub-set of lncRNAs that have been reported previously to exhibit 
significant expression change following genetic perturbation of PNN in the investigation of 
its role in alternative splicing of lncRNAs (Joo et al., 2013; Peixing et al., 2017). There have 
been no reported findings about this identified transcript in NSCLC. 
RNF139-AS1 is genomically located on chromosome 8q24.13 of the cytogenic band and its 
levels were significantly upregulated in the validation set in this study. 
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LANCL1-AS1 is a lncRNA located on chromosome 2q34. There is no previously published 
information available about its expression in NSCLC to the best of my knowledge. 
FENDRR (FOXF1 Adjacent Non-coding Developmental Regulatory RNA) is located on 
chromosome 16q24.1 and is believed to act by binding to PRC2 which are important in gene 
silencing. FENDRR has been reported to be important in the proper development of the 
heart and body of mice, down-regulated in gastric cancer tissues and cell lines, and involved 
in regulating metastasis by affecting fibronectin1 expression (Grote et al., 2013; Xu et al., 
2014). Navarro et al, in their computational study revealed that FENDRR regulates FOXF1 
expression in lung cancer by interaction with the promoter region of FOXF1 (Navarro et al., 
2016). However, there has been little or no published information available for its 
expression in NSCLC. Herrera-Merchan et al, have however suggested that both FENDRR 
and FOXF1 are silenced by DNA methylation in p53 mutated human lung cancer cells lines, 
and that expression of FOXF1 is regulated by FENDRR (Herrera-Merchan et al., 2016). 
LINC00968 (long intergenic non-coding RNA 968) is located on chromosome 8 (8q12.1) and 
was among the top 10 aberrantly expressed lncRNAs in LUSC according to studies by  Wen-
Jie et al., 2017. It has recently been shown to be significantly increased in LAD and LSCC 
tissues, as well as in NSCLC cell lines in comparison to controls (Wang et al., 2017). They 
further indicated that inhibition of LINC00968 brought about repression of NSCLC growth, 
migration and invasion. However, LINC00968 expression was repressed in NSCLC tissues in 
comparison to adjacent normal tissues, as well as in NSCLC cell lines in this investigation, 
and this finding correlates with studies carried out by Li et al, they observed LINC00968 to 
be significantly down regulated in LADC (Li et al., 2017c). 
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SVIL-AS1 (SVIL antisense RNA) is genomically located on chromosome 10p11.23. Findings 
from this study reveal that expression of this transcript is repressed in NSCLC tissues 
compared to normals, and no previous report of its expression and function has been 
published to date. 
PCAT19 (Prostate Cancer Associated Transcript 19) is located on chromosome 19 (19q13.8). 
The analysis carried out by Li et al. showed down-regulation of PCAT19 in LADC (Li et al., 
2017d). 
In conclusion, the findings of this study showed that 13 lncRNAs deregulated in NSCLC 
tissues were identified through the microarray analysis and predicted to be either induced 
or repressed (as seen in Table 3.1). qRT PCR validation analysis confirmed the microarray 
results (Figures 3.1 A-G and Figure 3.2 A-E), apart from LOC105376287 expression that was 
not upregulated in the validation sample sets. The expression change observed in tumours 
and normals was not significantly associated with the clinicopathological parameters. 
Comparative analysis of lncRNA expression with patient clinicopathological characteristics 
produced varying results. No significant differences were observed in the expression levels 
of all validated lncRNAs with age and histology. FEZF1-AS1 was higher in males compared to 
females (Mann Whitney’s Test, p=0.02), in contrast, high level of FEZF1-AS1 was not 
significantly correlated with gender in studies carried out by Jin et al. They however, 
reported an association between high expression level and tumour size, TNM stage and 
lymph node metastasis. Chen et al, also observed that patients with high expression of 
FEZF1-AS1 in colorectal cancer had advanced T-stage, lymph node, or distant metastasis 




4. EVALUATION OF EPIGENETIC INFLUENCE ON lncRNA DEREGULATION 
4.1. Introduction 
Epigenetic regulation is a key mechanism that is important in controlling developmental 
processes and disease development and progression (Liloglou et al., 2014). Abnormal gene 
promoter DNA methylation has been implicated in tumorigenesis and has become a target 
for developing strategies for early detection of cancer (Belinsky, 2004; Esteller, 2005 & Wu 
et al., 2016). In this study, we aimed to investigate the epigenetic causes of deregulation of 
the identified genes in NSCLC tumours and also to evaluate the influence of epigenetic 
modulators in some NSCLC cell lines. 
4.2. Promoter Methylation Levels of Selected lncRNAs in Tumour and 
Normal Tissues 
Pyrosequencing mediated DNA methylation analysis was undertaken for the promoters of 
those lncRNA target genes identified in this study that have a CpG island5 (FEZF1-AS1, 
PCAT6, NUTM2A-AS1, LINC00673, RNF139-AS1, FENDRR and SVIL-AS1). This was analysed by 
testing 1000 bp upstream exon 1 (including exon 1) in the online tool EBI 
(www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/), an example of which is shown in Figure 
4.1.  
                                                 
5
 A 200bp region of DNA having a GC content above 50% and an observed CpG versus expected CpG ratio 




Figure 4.1: An example of a Cpgplot showing the location of a CpG island identified in the 
FEZF1-AS1 promoter (the density of the CpG Island; the percentage of the C + G nucleotide 
content and the core promoter, based on standard conditions (Observed/Expected ratio> 
0.60, percent C + G> 50, Length > 200). 
 
DNA methylation analysis carried out on 129 NSCLC tumours and 36 normal tissues for 
which DNA was available. The threshold for significant methylation levels was set to 5%, as 
below this is considered technical noise (Shaw et al., 2006). The clinicopathological 
characteristics of these set of samples are given in Table 4.1. The mean age of the patients 
in this study was 65.57 and the male to female ratio was 88:41 respectively. From a 
histological perspective, patient samples comprised of 76 (58.9%) LSCCs and 52 (40.3%) 
LADCs. Most of the tumours were stage II disease [(107 (82.95%)] and 62% of patients had 
moderately differentiated carcinomas. 
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Table 4.1: Clinicopathological data of patients used for methylation analysis of identified 
lncRNAs 
 Methylation Set 
N 129 
Age 
Mean (s.d.) 65.57 (9.14) 
Gender 



















Well - Moderate 4 
Moderate 80 




Pyrosequencing analysis demonstrated that two out of the 7 genes (FEZF1-AS1 and FENDRR) 
were hypermethylated (Figures 4.2A and 4.2F). NUTM2A-AS1 and LINC00673 demonstrated 
a consistent and thus significant (regarding the derived p value) hypomethylation in the 
tumour tissue (as shown in Figures 4.2C and 4.2D). Despite the statistical significance of the 
changes  observed, the biological significance is questionable, considering the methylation 
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levels (which are ˂ 5% and therefore within the technical noise) (Shaw et al., 2006). PCAT6, 
RNF139-AS1 and SVIL-AS1 demonstrated no significant difference in DNA methylation 
between the normal or tumour tissues.  
The FEZF1-AS1 promoter was shown to be hypermethylated in tumour samples relative to 
the normal tissues (Mann Whitney test, p= 0.048). A representative pyrogram of the FEZF1-
AS1 promoter (Figure 4.3) shows the methylation levels of the individual CpG islands in 
tumour samples compared to normal lung tissues. Lower methylation levels were observed 
for NUTM2A-AS1 and LINC00673 in tumours compared to the adjacent normal tissues 
(Mann Whitney test, p=8.5 x 10-6 and 1.37 x 10-6 respectively). Representative Pyrograms 
showing methylation levels of FEZF1-AS1, FENDRR, NUTM2A-AS1 and LINC00673 are shown 
in Figures 4.3 to 4.6.  
Statistical analysis revealed no association between the DNA methylation deregulation 
shown in FEZF1-AS1, FENDRR, NUTM2A-AS1 and LINC00673 and the clinicopathological 
parameters (age, gender, histological sub-type, tumour/nodal staging and differentiation) in 
the examined sample set, indicating this deregulation is universal across histologies and 





E F G 
Figure 4.2: Scatter plots showing DNA methylation of 8 lncRNA promoters in NSCLC tumours and paired normal tissues. Mann-Whitney Test, p 
< 0.05 was considered significant. 
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Figure 4.3: Pyrogram showing the methylation of 6 positions in tumour and adjacent normal lung tissues of the FEZF1-AS1 promoter. 
Sequence analysed is shown at the top left of both tumour and normal samples. X-axis demonstrates the dispensation order. Examined 
CpGs are indicated by blue vertical zones while the bisulphite conversion control is denoted by the yellow vertical zone. The methylation 






28% 27% 28% 22% 
34% 42% 
AGTTTYGGTTGAAATTYGAGGTTTTGAAYGYGATTTTTTTYGATAGAAGTTGGGYGTTTTTTTTTATGTAATGTTGTAGT 

















Figure 4.4: Hypermethylation in the promoter region of FENDRR promoter can be observed for all the 7 CpG islands in tumour samples 
compared to the normal samples. The sequence analysed is shown at the top left of both tumour and normal samples. X-axis 
demonstrates the dispensation order. Examined CpGs are indicated by blue vertical zones while the bisulphite conversion control is 
denoted by the yellow vertical zone, while the methylation level of individual CpGs are shown at the top of each zone 
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Figure 4.5: Pyrogram showing the methylation levels at the promoter of NUTM2A-AS1 gene in tumour and normal lung tissues. All 9 CpG islands were 
hypomethylated in tumour and normal samples. The yellow bar is the internal quality control. CpG islands highlighted in red are indicative of error 
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Figure 4.6: Pyrogram showing the methylation levels at the promoter of LINC00673 gene in tumour and normal lung tissues. CpG islands highlighted 






0% 0% 0% 0% 0% 0% 0% 4% 0% 
6% 5% 4% 0% 4% 0% 3% 0% 0% 
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4.3. Influence of Epigenetic Modifiers on NSCLC Cell Lines 
In order to gain additional evidence on the potential epigenetic control of the identified 
lncRNAs, we studied the impact of two epigenetic modifiers, namely 5-aza-deoxycytidine 
(DAC) and valproic acid (VPA), on their levels in 4 NSCLC cell lines (A549, CALU6, H358 and 
SKLU1). The efficiency of DAC on cell lines was assessed by measuring global DNA 
methylation using the LINE1 repetitive element sequence (Daskalos, 2009). Line1 being a 
gold standard for the measurement of global methylation is used in this study to show that 
methylation differences in lncRNA promoters were not primarily following global 
demethylation trends, therefore there might be certain selective advantages for the tumour 
biology. 
From our findings, we observed that the use of LINE1 in the cell lines showed reduced levels 
of global methylation of LINE1 in SKLU1 cell line after treatment with DAC compared to the 
control. SKLU1 untreated cells had a methylation index of 62%, while DAC treated cells had 
a reduced methylation index of 41%. Methylation index of LINE1 in the untreated H358 cell 
line was only 51% (which did not signify heavy methylation), however, there was a marked 
reduction in the DAC treated cell line (37%). No significant difference was observed between 
control and DAC treated A549 and CALU6 cell lines. There was no change observed in all the 
cell lines treated with VPA, but it is interesting to observe a potentiating effect in VPA/DAC 
treated H358 and SKLU1 cell lines.  A summary of the results obtained for all the cell lines 
and a representative pyrogram for SKLU1 are shown in Table 4.2 and Figure 4.7 respectively. 
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Table 4.2: Methylation status of LINE1 in cell lines before and after treatment with DAC and 
VPA. Results are presented as means of 3 technical replicates. 
 
Control DAC VPA VPA/DAC
A549 54 49 53 51
CALU6 44 41 44 39
H358 51 37 51 38






Figure 4.7: Representative pyrogram showing the methylation status of LINE1 in the untreated SKLU1 and the SKLU1 cell line exposed to DAC. 
Hypomethylation of LINE1 can be observed following treatment with DAC. The sequence to be analysed is shown at the top left of both 
pyrograms, and percent methylation of individual CpG sites indicated at the top of the grey-shaded positions. 
62% 70% 62% 56% 77% 45% 
38% 47% 41% 42% 43% 31% 
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Levels of the individual lncRNAs with or without the epigenetic modifiers are shown in 
Figure 4.8. FEZF1-AS1 level analysis showed varying levels in the different cell lines and the 
results were compared with controls.  A549 and CALU6 did not express FEZF1-AS1 and 
treatment with DAC had no effect on its expression in both cell lines; however, its 
expression was found to be altered by VPA and VPA/DAC in A549, and by VPA in CALU6. A 
similar expression pattern was observed for H358 and SKLU1, expression of FEZF1-AS1 was 
reduced following DAC treatment in H358 and SKLU1. A synergistic effect was observed for 
combination treatment with VPA/DAC in H358 significantly (Figure 4.8). LINC01214 gene 
expression was increased after treatment with DAC in A549, CALU6 and SKLU1. In contrast, 
expression of LINC01214 in H358 and SKLU1 was significantly increased with VPA/DAC 
treatment (Figure 4.8). There was a trend of reduced expression of LOC105376287 in DAC 
treated A549, H358 and SKLU1 (Figure 4.9) and all the VPA treated A549, CALU6, H358 and 
SKLU1. Expression of PCAT6 was increased in VPA treated A549, H358 and SKLU1, and a 
synergistic effect could be observed in VPA/DAC treated A549 and SKLU1. However, its 
expression was reduced in DAC treated A549, H358 and SKLU1 (Figure 4.9).  
DAC treated CALU6 and H358 showed increased expression of LOC101927229, while a lower 
expression was observed in SKLU1 treated with DAC, VPA and VPA/DAC (Figure 4.10). 
LINC0073 expression was reduced in DAC treated A549, H358 and SKLU1, as well as in VPA 
treated A549, CALU6 and H358 (Figure 4.10). There was no significant difference in 
expression of NUTM2A-AS1 expression in all the treated cell lines compared to the controls 
(Figure 4.11). Expression of RNF139-AS1 was reduced in A549 exposed to DAC and VPA; 




Figure 4.8: Bar chart representation showing FEZF1-AS1and LINC01214 levels in A549, CALU6, H358 and SKLU1 NSCLC cell lines following 
treatment with of DAC and VPA. DAC treatment is shown to increase LINC01214 levels in A549, CALU6 and SKLU1 consistently. Error bars are 




Figure 4.9: Bar chart representation showing LOC105376287 and PCAT6 levels following treatment with DAC, VPA and a combination of both. 




Figure 4.10: Bar chart showing effect of DAC and VPA on LOC101927229 and LINC00673 in the A549, CALU6, H358 and SKLU1 cell lines. DAC 




Figure 4.11: Bar chart representation of NUTM2A-AS1 and RNF139-AS1 levels in some cell lines after exposure to DAC and VPA.In the presence 





There are different mechanisms by which lncRNAs appear to regulate gene expression, 
however, epigenetic mechanisms are known to play a crucial role in regulating gene 
expression and are involved in the development of cancer. Several studies have shown that 
about 20-30% of lncRNAs have been able to physically interact with specific epigenetic 
enzymes, driving them to specific genomic loci (Karapetyan et al., 2013). This interaction 
with chromatin-modifying proteins, like PRC2 and CoREST, results in modulation of the 
chromatin states thereby controlling normal biological processes (Cheetham et al., 2013), 
while interaction with promoters and transcription factors control transcription of genes in 
cis or trans resulting in gene silencing etc.(Qureshi et al., 2010). Epigenetic mechanisms (like 
DNA methylation, histone modification and ncRNAs) control the access of transcriptional 
machinery to their target genes thereby modulating transition from the condensed 
heterochromatin to relaxed euchromatin and vice versa. These are synergistically operated 
to regulate the chromatin structure and to achieve the required degree of gene expression 
needed for normal biological processes (Seidel et al., 2012;  Liloglou et al., 2014). The 
methylation of CpG islands in the promoter region of genes is known to result in gene 
silencing and there is an established link between aberrant global DNA methylation and 
genomic instability (Jones and Takai, 2001). 
 lncRNAs deregulation a probable cause for the onset and development of epigenetic 
diseases, including cancer (Zhao et al., 2016). Feng et al, in their study linked lncRNA 
deregulation and DNA methylation in NSCLC (Feng et al., 2016). In this study, methylation 
changes were shown in the promoters of FEZF1-AS1, FENDRR, NUTM2A-AS1 and LINC00673.  
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From our findings, we observed that aberrant DNA methylation occurs in NSCLC tumour 
tissues when compared to their adjacent paired normals. We identified two 
hypermethylated and two hypomethylated lncRNA genes, which, to our knowledge have no 
published report of their expression or methylation status. FEZF1-AS1 expression was 
induced in NSCLC tumours and was found to be hypermethylated in this study. Although 
promoter hypermethylation is associated with gene silencing (repression), FEZF1-AS1 was 
shown to be overexpressed in NSCLC tumour tissues. Global DNA hypomethylation (mainly 
associated with repeated DNA) and hypermethylation in non-repeat DNA stretches of gene 
promoter sequences have been reported to contribute in cancer development and it has 
been revealed that DNA hypomethylation at the promoter regions of oncogenes can 
activate their expression, while DNA hypermethylation at the promoters of tumour 
suppressor genes can lead to their silencing (Ehrlich, 2002; Ehrlich, 2009). Although 
promoter hypermethylation is associated with gene silencing, FEZF1-AS1 is hypermethylated 
but also upregulated in NSCLC tumours compared to adjacent normal tissues. It has been 
reported to act as an oncogene in gastric cancer and as an anti-oncogene in pancreatic 
cancer (Liu et al., 2017). The methylation status of FEZF1-AS1 promoter in gastric and 
pancreatic tumours is unknown. FEZF1-AS1 may be acting as an oncogene in NSCLC. FENDRR 
gene expression was shown to be repressed in tumours compared to the normal lung 
tissues and was also significantly hypermethylated in lung tumour tissues (Figures 4.6 and 
4.9), this finding agrees with the gene silencing function of promoter methylation. Several 
lncRNAs that are down regulated in cancer are shown to act as tumour suppressor genes 
(MEG3 , GAS6-AS1 , BANCR have all been reported to be significantly down-regulated in 
NSCLC tissues and other malignancies) (Lu et al., 2013; Han et al., 2013; Sun et al., 2014). 
NUTM2A-AS1 and LINC00673 are two lncRNAs overexpressed in NSCLC but also 
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hypomethylated at their promoters. Udomsinprasert et al have reported an association 
between promoter hypomethylation and overexpression (Udomsinprasert et al., 2017). DNA 
hypomethylation has also been linked to overexpression of PLS3, GATA6, and TWIST1 in 
Sezary Syndrome (Wong et al., 2015). For over 30 years, aberrant promoter 
hypermethylation that results in silencing of tumour suppressor genes in cancer has been 
the focus of several studies and have led to the development of DNA hypomethylating 
therapeutic agents to reverse DNA hypermethylation. However, the emergence of new 
high-resolution methylation profiling techniques, like whole genome bisulfite sequencing 
(WGBS), have revealed that the methylome of cancer cells frequently contain promoters 
that are hypomethylated in comparison to their paired normal cells. Such aberrant 
hypomethylation has been shown to be frequently accompanied by increased gene 
expression at differentially methylated loci (Upchurch et al. 2016).  The hypomethylation of 
the promoter regions of NUTM2A-AS1 and LINC00673 may be responsible for increased 
expression of this lncRNAs and they may be acting as oncogenes. 
DNA methylation is an early event in tumourigenesis, and the profiling of global methylation 
can lead to identification of disease-state biomarkers and early diagnosis. Several studies 
have used pyrosequencing of LINE1 assay as a standard method for studying global DNA 
methylation (Yang et al., 2004; Lisanti et al., 2013; Delaney et al., 2015).  LINE1 (long 
interspersed nuclear elements 1) are repetitive elements that are abundant in the human 
genome (making up approximately 17% of the genome i.e. about 500,000 copies per 
genome). They are relatively inactive, majorly due to 5’ truncations (Lander et al., 2001, 
Kazazian, 2004), however, the prevalence of CpG islands and the associated aberrant DNA 
methylation (hypomethylation and hypermethylation) in these regions of the genome is 
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reported to cause the retrotransposition of these elements resulting in diseases like cancer 
etc. (Portela and Esteller, 2010). Loss of methylation at repeat elements has also been 
reported to be associated with increased chromosomal instability, aggressive development 
of colorectal cancer and NSCLC (Igarashi et al., 2010; Saito et al., 2010).). 
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5. FUNCTIONAL IN VITRO ANALYSIS OF LINC00968  
5.1. Introduction 
lncRNAs have diverse functions, however, to date we only understand the function of a 
small proportion of the known lncRNAs. While the observation of lncRNA deregulation in 
lung cancer (which was the starting point of this study) is very important, it is imperative to 
understand the functional relevance of our identified lncRNAs in NSCLC and explore their 
functional contribution to cell phenotype and/or drug resistance if any.  
We selected LINC00968 one of the top repressed lncRNAs in our study (Figure 3.2C), for 
further analysis. In order to examine the biological importance of LINC00968 in NSCLC, we 
overexpressed the gene in A549 cell line and assessed the phenotypic changes including 
potential modulation of resistance to commonly used chemotherapeutic drugs in NSCLC. 
5.2. LINC00968 Selection and Cloning 
LINC00968 was chosen for further studies because of its evident low levels as observed in 
our microarray study, the fact that its expression was completely diminished in most of the 
tested lung cancer cell lines (See Appendix V) and the extremely limited knowledge available 
on its function in the literature [Li et al, in their study also showed that LINC00968 was 
differentially expressed in tumours compared to normals (Li et al., 2017c)].  
Because of the apparent absence of expression observed in tissues and cell lines, we 
hypothesized that LINC00968 could be functioning as a tumour suppressor in NSCLC; 
therefore, the restoration of expression could potentially reverse malignant phenotype. 
To achieve the above objective, the pTarget_968 plasmid was generated to induce 
LINC00968 expression as described in Section 2.2.8.3. Following which, the A549 lung 
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adenocarcinoma cell line was transfected with the plasmid to generate stable clones 
expressing the gene.  
Transcript levels of LINC00968 in A549 parental cell and the clones was assessed by qRT 
PCR. LINC00968 levels was not detected in A549 parental cell line, Clones 3, 6, 7, 8, 10 and 
11. However, variable levels of the gene were detected in Clones 1, 2, 4, 9 and 12, and Clone 
2 was chosen as a reference (set to 100%) because it demonstrated the highest level of 
LINC00968 (Figure 5.1). To assess its level for comparative purposes, all other clones were 
measured in reference to Clone 2 shown in Table 5.1.  
 
Figure 5.1: Bar chart showing LINC00968 levels in A549 parental cell line and the different 
clones following transfection with pTarget_968. The order follows the pattern of the qRT 




Table 5.1: Comparative levels of LINC00968 in the A549 parental cell line and the Clones as a 
percentage in reference to Clone 2. 
 
5 of the clones (2 representing maximum transcript levels, 4 as high levels, 9 as moderate 
levels, 12 as low levels and 7 acting as vector only) were selected for the evaluation of 
functional relevance of the LINC00968 lncRNA in the different assays and drug treatments. 
5.3. MTT Assay 
The ability to proliferate is one of the hallmarks of cancer cells, therefore, cell proliferation 
rate was assessed using the MTT assay as described in Section 2.2.9.1. Although this assay 
measures cell metabolic activity, it is commonly used in assessing proliferation rates. 
Interestingly, the greater repression in proliferation was not demonstrated in the clones 
expressing high levels of LINC00968 but in the clone with lower levels (Figure 5.2), while 
further increased levels demonstrated a tendency toward the proliferation rates of parental 
or vector only cell. This is interesting but also difficult to interpret at this point, as the 
physiological levels of LINC00968 are not well understood and comparison to the normal 
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human lung tissue is not technically valid, given the fact that the latter is a mix of different 
cell types. 
 
Figure 5.2: Line graph showing the viability of the parental A549 cell line and the respective 
selected Clones. Higher proliferation rate was observed for the A549 parental cell line in 
comparison to the Clones. Error bars are representative of 95% confidence interval. 
 
5.4. Anchorage Independence Assay 
The ability of transformed cells to grow independently of a solid surface is another hallmark 
of tumourigenesis, therefore in this study we explored the anchorage independent activity 
of the parental A549 and the selected A549_linc00968 clones as described in Section 
2.2.9.2. We observed that the presence of LINC00968 reduces the cell line’s anchorage 
independent growth (Figure 5.3a), and reduction in cell colony counts reflects the inhibition 







Figure 5.3a; Images of anchorage independent growth assay of A549 arental cell and 
A549_LINC00968 overexpressing clones. The number of colonies created was inversely 
correlated with the amount of LINC00968 expressed by the cells (there was a marked 
decrease in cell colony count between the A549 parental, A549_LINC00968 clone 7 and the 






Figure 5.3b: Graph showing the inverse correlation between the relative expression of 
LINC00968 and the cell colony count.  
Table 5.2: Reduction in cell colony count observed following anchorage –independent 
growth analysis. Percentage expression is relative to LINC00968 levels in Clone 2.  
Cell Line/ Clones Cell Count (Average)  
A549 parental (0 expression) 630 
Clone 7 (0 expression) 590 
Clone 9 (53% expression) 320 
Clone 4 (75% expression) 290 
Clone 2 (100% expression) 210 
 
5.5. Migration and Invasion Assay 
Cancer metastasis is a complex and multistep process that is extremely related to cell 
motility, and also to the migratory and invasive potentials of cancer cells (Webb et al., 
2011). Cancer cells spread by migrating and invading extracellular matrixes (ECM), entering 
into the blood circulation, attaching to distant sites, and finally erupting to form distant foci 





Wound Healing Assay 
The wound healing assay as described in Section 2.2.9.3 was used to determine the role of 
LINC00968 in cell migration and interaction. Figures 5.4 (A – B) shows the gap area created 
by the wound analysed over time, the difference in gap area for the A549 parental cell line 
compared to the clones was taken over a 72-hour period. A complete closure of the wound 
area was observed at 72 hours for A549 parental cells and empty vector (Clone 7), both of 
which do not show detectable levels of the LINC00968 . In contrast, the gaps in clones 2 and 
4 (maximum and high LINC00968 Clones) were not completely closed. 
 
Figure 5.4: Scratch assay image showing extent of wound closure (A) between the A549 
parental and the different Clones at 0h and 72h. (B) Wound closure in the A549 parental cell 





Boyden Chamber Assay  
We went on further to explore the metastatic and invasive effects of LINC00968 in our A549 
parent cell line and selected A549 LINC00968 Clones using an adaptation of the Boyden 
Chamber Assay (Section 2.2.9.4).  
There was markedly repressed migration observed in Clones 2 and 4 (maximum and high 
LINC00968 levels respectively) compared to A549 parental cell and empty vector (Figure 
5.5A). Presence of LINC00968 also had an effect on invasion, reduction in number of cells 
can be observed in the Clones with maximum and high levels of LINC00968 compared to the 
A549 parental and vector only which both had undetectable levels of the LINC00968 lncRNA 





Figure 5.5: Migratory and invasive effect of LINC00968 on the A549 parent cell line and the 
different A549 LINC00968 Clones. (A.)  Migration assay in the absence of Geltrex matrix: 
overexpression reduced migration in the A549 clones with 100% and 75% elevated levels. 
(B.) Invasion assay using Geltrex matrix: marked reduction in invasive ability of LINC00968 
expressing Clones was observed compared to A549 parental and the vector only clone. 
 
5.6. LINC00968 and Oxidative Stress 
In order to assess the potential impact of LINC00968 as an antioxidant in the cell’s response 
to oxidative stress, the A549 parental cell line and the derivative clones were exposed to 
different concentrations of H2O2. Viability was measured using the MTT assay.  
As it becomes evident from Figure 5.6, that low concentrations (25 M) of H2O2 
overexpression of LINC00968 appears to have a negative impact on cell viability. Τhe effect 
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is almost proportional to LINC00968 levels. Dunnet’s post-hoc test demonstrated 
differential significance (p=0.107, p= 0.026, and p=0.008 for the clones 9, 4 and 2 
respectively) between parental and LINC00968 overexpressing clones while there was no 
significance between parental and the vector only clone (p=0.661).  At higher 
concentrations this effect is minimised. A significant difference was observed in all clones at 
150 M, however, the viability of cells is already limited and there is no difference between 










5.7. Impact of LINC00968 Expression on Drug Resistance 
Resistance to anti-cancer drugs is one of the major reasons for the failure of lung cancer 
treatment. In this study, the role of LINC00968 in modulating resistance ito some widely 
used drugs in lung cancer was investigated. A549 parental cell and selected A549 LINC00968 
clones were exposed to fluorouracil (5FU), gemcitabine, cisplatin, vinorelbine, methotrexate 
and pemetrexed to assess the potential modulation of resistance to commonly used 
chemotherapeutic drugs in NSCLC and their involvement in molecular pathways associated 
with the use of these drugs 
Following drug treatment with 5FU, there was no significant difference in cell viability of the 
Clones (2, 4, 9, 12, 7) and the A549 parental cell line (Figure 5.7, Kruskal Wallis test p=0.37), 
irrespective of the expression level of the LINC00968.  However, there was a statistical 
difference detected in the untreated cells and the clones expressing LINC00968 (Figure 5.7C 
Mann Whitney test p=5.6 x 10-5).  
The results obtained for gemcitabine and cisplatin were similar with no significant difference 
observed in relative cell survival between the A549 parental cell line, the empty vector and 
the selected clones (Figure 5.8 and 5.9). 
Exposure of the A549 parental and Clones to methotrexate and pemetrexed showed a 
difference in cell viability. Clones 2, 4 and 9 demonstrated an increase in relative cell survival 
in an expression dependent manner compared to the parental cell and vector only. 
LINC00968 may be involved in increasing the sensitivity of cancer cells to methotrexate and 





Figure 5.7: Bar chart and simple error bar showing cell viability response of the A549 
parental cell and the respective Clones to 5-FU and their corresponding LINC00968 level. 
Significant effect on cell viability can be observed in the untreated cells. Error bars represent 








Figure 5.8: Bar chart and simple error bar showing cell viability response of the A549 
parental cell and the respective Clones to Gemcitabine and their corresponding LINC00968 
levels. There is no statistical difference in cell viability of treated and untreated cells. Error 






Figure 5.9: Bar chart and simple error bar showing cell viability response of the A549 
parental cell and the respective clones to Cisplatin and their corresponding LINC00968 
levels. No statistical difference was observed in cell viability of treated and untreated cells. 







Figure 5.10: Bar chart and simple error bar showing cell viability response of the A549 
parental cell and the respective Clones to Vinorelbine and their corresponding LINC00968 







Figure 5.11: A.] Effect of methotrexate on cell viability, showing significant cell survival in 
the Clones expressing LINC00968 compared to A549 parental cell and the empty vector. B.] 
Corresponding LINC00968 levels of the A549 parental cell line and the clones C.] Survival 
ratio between the treated and untreated. Error bars are representative of 95% confidence 
interval. 







Figure 5.12: Effect of Pemetrexed on the A549 parental cell line and the different clones, 
showing significant cell survival in the clones expressing LINC00968 compared to A549 
parental cell and the empty vector. B.] Corresponding LINC00968 expression levels of the 
A549 parental cell line and the clones C.] Survival ratio between the treated and untreated. 
Error bars are representative of 95% confidence interval. 
  







LINC00968 was selected for functional study as one of the top repressed lncRNAs identified 
in our study and having minimal information on its function. A recent publication reported 
its upregulation in NSCLC, and that its inhibition repressed growth, migration and invasion 
by activating the Wnt signalling pathway (Wang et al., 2018).  Although their findings do not 
correlate with the findings in our study, the possibility of the upregulation and 
downregulation of a gene promoting cancer in the same cell has been reported by Wang et 
al, who demonstrated that SRPK1 (serine-arginine protein kinase 1) was shown to be either 
downregulated or overexpressed and that this aberrant expression of SRPK1 in either 
direction brings about modulation of the Akt pathway (Wang et al., 2014). Similarly, there 
are numerous signal molecules that have demonstrated tumour suppressing and oncogenic 
functions in different cells (Feng, 2012).  
Interestingly, the lowest proliferation rates were observed in clone 12, which was the clone 
with the least LINC00968 levels. This is not currently understood, however, it is not 
necessarily a paradox; since the physiological levels of LINC00968 gene expression are 
unknown and the 100% expression used in this study as a comparative term is an arbitrary 
selection referring to the highest achieved overexpression through our inducible system and 
not the physiological one.  
In contrast to proliferation, the presence of LINC00968 in A549 also resulted in suppression 
of anchorage independence in almost a proportional manner. Many cell types are known to 
require a form of anchorage dependence to survive, anchorage independence is therefore a 
phenotypic characteristic of transformed cells, and this has been linked to metastasis. A 
more moderate but clear effect was observed in migration and invasion properties of the 
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LINC00968 overexpressing clones, demonstrating suppression of both characteristics but in 
a manner not proportional to the level of the lncRNA. While cell migration by definition is 
the movement of individual cells, cell sheets and clusters from one location to another, cell 
invasion on the other hand is the 3-dimensional migration of cells as they penetrate an 
extracellular matrix (ECM) and is a process typically associated with cancer cell metastasis 
(Hulkower & Herber, 2011). Both cell migration and cell invasion occur as a result of 
epithelial-mesenchymal transition (EMT), which though integral to development have been 
shown to be reactivated in wound healing, fibrosis and cancer progression (Kalluri & 
Weinberg, 2009). Several molecular processes are involved in the initiation and completion 
of the EMT process and these include the activation of transcription factors, expression of 
specific cell-surface proteins, reorganization and expression of cytoskeletal proteins, 
production of ECM-degrading enzymes, changes in the expression of specific microRNAs 
(Kalluri & Weinberg, 2009) and more recently changes in the expression of lncRNAs in 
cancer (Dhamija, & Diederichs, 2016). We can state that LINC00968 is an important 
regulator of migration and invasion in NSCLC in vitro, however, we are yet to understand the 
mechanism by which this is accomplished. 
Oxidative stress is an important factor for cancer cell growth and survival, especially when 
tumours are treated with radiation therapy and certain types of chemotherapy (Conklin, 
2004; Chen et al, 2007; Morry et al, 2017). We therefore tested the impact of LINC00968 
expression on oxidative stress. It is apparent that, under low H2O2 concentrations, 
restoration of LINC00968 expression leads to reduced viability (Figure 5.6). As the function 
of LINC00968 is not yet known, it is not possible to speculate the underlying mechanism. 
The next reasonable experiment to perform is to test apoptosis, hypothesizing that 
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LINC00968 expression triggers programmed cell death in the presence of oxidative stress, 
however there was not enough time to perform this experiment.  
At higher H2O2 concentrations this effect is lost as the overall viability is gradually being 
reduced. One can hypothesize that as other molecules may be triggering cell death at those 
concentrations, the effect of LINC00968 is hidden or indeed the function of the gene may 
become obsolete. The clarification of the mechanistics behind this observation opens an 
interesting research question and requires further investigation. At this point, the statistical 
difference seen at the highest H2O2 is not considered of any biological importance because 
the overall viability of all cells is low and the only difference is seen in the vector only clone, 
so it is considered circumstantial and irrelevant to LINC00968 expression. 
Chemotherapy is a major tool of treatment for the management of all cancers; however, the 
drug resistance development is by far the most important problem for successful treatment 
of cancer across a wide range of anti-cancer drugs. Drug resistance occurs not only due to 
individual pharmacogenetic variations in patients, but also as a result of genetic and 
epigenetic differences in tumours themselves. Recent studies have revealed that lncRNAs 
play a vital role in drug resistance in different cancers including lung cancer. Dysregulation 
of multiple targets and pathways by lncRNAs have been shown to result in the occurrence of 
drug resistance. HOTAIR has been shown to target P21 in NSCLC resulting in resistance to 
cisplatin, GAS5 targets IG-1R to bring about gefitinib resistance in NSCLC and MEG3 
contributed to cisplatin resistance in NSCLC by targeting P53 and bcl-xl (Chen et al, 2017). 
We investigated LINC00968 involvement in resistance of 6 anti-cancer drugs, commonly 
used in NSCLC therapy, to get a first impression of the involvement of this lncRNA in drug 
resistance. Overexpression of LINC00968 did not have a significant effect on the cell survival 
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when compared to the A549 parental cell and the empty vector for fluorouracil (5FU), 
gemcitabine, cisplatin and vinorelbine. On the contrary, exposure to methotrexate and 
pemetrexed demonstrated that cells expressing LINC00968 were more resistant to these 
drugs, compared with the A549 parental and the empty vector. While at the moment it is 
very difficult to draw conclusions of the mechanism involved in this resistance, it is safe to 
exclude the possibility of this being a secondary effect of the low proliferation rate that 
LINC00968 induces. Both methotrexate and pemetrexed bind to DHFR (dihydrofolate 
reductase) enzyme inhibiting the conversion of folate to tetrahydrofolate, consequently 
affecting DNA synthesis and cell growth (Chen et al., 1984; Zhang et al., 2011). Although 
pemetrexed is also involved in the inhibition of thymidylate synthase (TS) and glycinamide 
ribonucleotide formyltransferase (GARFT) enzymes in the folate pathway, we suggest that 
LINC00968 may be involved in methotrexate and pemetrexed resistance by interacting with 
the DHFR binding site. 
The phenotypic changes induced by LINC00968 overexpression in A549 cell line, while 
encompassing some variability, clearly demonstrate the negative impact of this lncRNA in 
proliferation, migration and invasion. LINC00968 therefore demonstrates the properties of a 








6. CONCLUSION AND FUTURE WORK 
6.1. Conclusion 
This study is one of the very few comprehensive screenings of lncRNA expression in NSCLC. 
It successfully demonstrated that a number of lncRNAs are differentially expressed in NSCLC 
tumours when compared with paired normal tissues.  We identified 20 upregulated and 30 
down regulated lncRNAs through the expression microarray analysis and validated the top 
13 by qRT PCR. We showed that the expression pattern of selected top induced (FEZF1-AS1, 
LINC01214, , PCAT6, LOC101927229, LINC00673, NUTM2A-AS1 and RNF139-AS1), and top 
repressed (LANCL1-AS1, FENDRR, LINC00968, SVIL-AS1, and PCAT19) lncRNAs in our 
expression microarray was consistent with results obtained following qRT PCR validation 
except for LOC105376287. We discovered 6 uncharacterized lncRNAs (LOC105376287, 
LOC101927229, NUTM2A-AS1, RNF139-AS1, SVIL-AS1 and PCAT19) in our study and have 
been able to determine their expression pattern in NSCLC tissues and a number of NSCLC 
cell lines.  
There have been no major correlations with clinical descriptors, indicating that their 
deregulation is a universal phenomenon in NSCLC and most likely appear early in tumour 
development. It is possible that FEZF1-AS1, LINC00968, LOC101927299 and PCAT6 may be 
valuable as surrogate diagnostic markers in NSCLC but this will be subject to their 
detectability in clinical specimens such as blood, sputum or bronchial washings.  
We also investigated DNA methylation as a potential molecular reason for the observed 
deregulation of those lncRNAs levels. We established that FEZF1-AS1 and FENDRR were 
hypermethylated, while NUTM2A-AS1 and LINC00673 were hypomethylated, suggesting 
that epigenetic control of these lncRNAs is important in lung cancer development. These 
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results were strengthened by the in vitro analysis of FEZF1-AS1 and LINC00673 expression, 
following exposure to DNA methylation histone deacetylase inhibitors in four NSCLC cell 
lines. These experiments have clearly demonstrated the differential action of DAC and VPA 
on the different cell lines emphasizing on the dependence of the drug efficacy on the 
existing combination of genome and epigenome of tumour cells. 
Finally, we selected one of the deregulated lncRNAs (LINC00968) for functional in vitro 
analysis.  Restoration of expression of LINC00968 in A549 cells demonstrated a clear shift in 
the phenotype. While the inhibition of proliferation was not proportional to LINC00968 
levels, a clearer inverse correlation was observed between LINC00968 levels and anchorage-
independent growth, LINC00968 overexpression also repressed migration and invasion. One 
of the most interesting findings of this thesis is that LINC00968 modulated resistance to 
methotrexate and pemetrexed in LINC00968 expressing A549 cells. These are very popular 
second line chemotherapeutics used in NSCLC treatment and further research should be 
undertaken to establish the potential clinical value of this observation. 
6.2. Future Work 
The results from this study pose interesting research questions on two levels: cancer biology 
and clinical utility. On the first front, a major goal for future research will be to explore the 
relationship between the expression of identified lncRNAs and the expression of any 
associated mRNAs and proteins to enhance our understanding of the specific 





6.2.1 Explore lncRNAs interactions to related mRNAs/proteins. 
 
LINC00968 has been  shown to act as an oncogene in NSCLC by activating the Wnt signalling 
pathway, although the findings suggested that LINC00968 was significantly increased in LAD 
tissues, LSC tissues and NSCLC cell lines (Wang et al., 2018), which was contrary to our 
findings. It was also found to play an important role in the reduction of drug resistance in 
breast cancer cells by inhibiting the Wnt2/B-catenin signalling pathway through silencing 
Wnt2 (Xiu et al., 2019). Therefore, it is of interest to consider examining the Wnt signalling 
pathway and any associated mRNA/protein in relation to LINC00968 down regulation in 
NSCLC. 
Experiment to enable the identification of mRNAs and/or proteins associated with down 
regulation of LINC00968 will be carried out. To achieve this, RNA immunoprecipitation (RIP) 
and/or Chromatin immunoprecipitation (ChIP) technique will be employed using total RNA 
extracted from patient samples available from the Liverpool Lung Project Biobank. Cells will 
be cultured and harvested following the recommended protocol, the harvested cells will 
then be lysed and LINC00968 co-precipitated with the protein of interest from the lysate. 
The RIP procedure involving the antibody prebinding step, cross-linking and wash step is 
performed, after which protein analysis (using western blot) and RNA analysis (using RT 
qPCR) may be carried out to analyse the protein or the RNA associated with LINC00968. 
6.2.2  In vitro functional analysis on a selected lncRNA target 
 
Of the 13 lncRNAs selected for further studies following the microarray analysis, only 
LINC00968 was evaluated for functional in vitro analysis in this study, it is important 
therefore that the other lncRNAs targets be studied. Of interest is the LOC101927229 that 
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was found to be upregulated in the microarray analysis and further validated by qPCR to be 
significantly upregulated in tumours compared to the adjacent paired normals. 
LOC101927229 is still uncharacterised and to date no information is available to the best of 
my knowledge. To carry out in vitro functional analysis, shRNA knockdown protocol will be 
employed. LOC101927229 was shown to be upregulated in the LUDLU1 NSCLC cell line, 
consequently LUDLU1 will be used for the knockdown experiment. shRNA construct for 
LOC101927229 and negative control will be purchased,  primer design will be done using the 
Primer3 Input (and purchased), while LUDLU1 cells will be cultured and plated under the 
recommended conditions and protocols before transfection using the FuGENE Transfection 
Reagent kit. LOC101927229 shRNA will be transfected into LUDLU1 cell line. Following 
successful knockdown, clones with over 50% efficiency will be used for functional studies 
(cell proliferation, migration and invasion). 
6.2.3  Identified lncRNAs as a biomarker in non-invasive samples 
Finally, at the clinical utility front, the levels of the discovered lncRNAs will be tested in 
clinical samples such as sputum, plasma and bronchial washings, in order to determine their 
value as biomarkers for clinical management of the disease. 
The high stability of lncRNAs while circulating bodily fluids makes them suitable for 
development as biomarkers that are none or minimally invasive. For a lncRNA to be 
considered as a biomarker (putative, prognostic, diagnostic or predictive), it must be 
differentially expressed in tumours compared to the adjacent normal tissues and validated 
by qPCR to be differentially expressed. It should also be measurable and specific. Although 
LINC00968  was shown to be down regulated in the microarray results, which was confirmed 
by qPCR, it can be considered a putative biomarker, as further studies are still needed to 
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establish its specificity and availability in non-invasive samples. The biomarker screening will 
target a sub-population of the elderly (65 years and above in both men and women).  
It will also be interesting to look at LOC101927229, PCAT6 and LANCL1-AS1 in relation to 
their potential as prognostic biomarkers due to their correlation with some of the 
clinicopathological parameters. We may also in the future consider biomarker development 
from elevated tumours, as it will enable the use of the siRNA or shRNA for knockdown 
experiments. Identification of biomarkers will aid in early detection of lung cancer, increase 
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A3 CORL23 LINC968 Undetermined 
    
A3 CORL23 TBP 27.77 
B3 CORL23 LINC968 Undetermined 
    
B3 CORL23 TBP 27.68 
A9 H358 LINC968 25.61 -1.38 
   
A9 H358 TBP 26.99 
B9 H358 LINC968 25.76 -1.26 
   
B9 H358 TBP 27.02 
A10 HBEC3KT LINC968 27.01 -0.20 
   
A10 HBEC3KT TBP 27.21 
B10 HBEC3KT LINC968 41.92 14.29 
   
B10 HBEC3KT TBP 27.63 
A12 HBEC3KT 53 LINC968 27.84 -0.93 
   
A12 HBEC3KT 53 TBP 28.78 
B12 HBEC3KT 53 LINC968 28.07 -0.59 
   
B12 HBEC3KT 53 TBP 28.66 
A11 HBEC3KT R LINC968 Undetermined 
    
A11 HBEC3KT R TBP 27.68 
B11 HBEC3KT R LINC968 Undetermined 
    
B11 HBEC3KT R TBP 27.65 
C1 HBEC3KT R53 LINC968 42.80 15.10 
   
C1 HBEC3KT R53 TBP 27.70 
D1 HBEC3KT R53 LINC968 42.36 14.73 
   
D1 HBEC3KT R53 TBP 27.62 
A7 LUDLU1 LINC968 27.11 -1.78 
   
A7 LUDLU1 TBP 28.89 
B7 LUDLU1 LINC968 27.04 -1.76 
   
B7 LUDLU1 TBP 28.80 
A8 LUNG14 LINC968 26.21 -2.26 
   
A8 LUNG14 TBP 28.47 
B8 LUNG14 LINC968 26.30 -2.13 
   
B8 LUNG14 TBP 28.43 
A4 SKLU1 LINC968 43.89 16.08 
   
A4 SKLU1 TBP 27.81 
B4 SKLU1 LINC968 48.43 20.62 
   
B4 SKLU1 TBP 27.81 
A6 SKMES LINC968 Undetermined 
    
A6 SKMES TBP 26.95 
B6 SKMES LINC968 Undetermined 
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